This company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsRockley Photonics Holdings (RKLY.Q) 주식 개요Rockley Photonics Holdings Limited develops and supplies silicon photonics in the United Kingdom and internationally. 자세히 보기RKLY.Q 펀더멘털 분석스노우플레이크 점수가치 평가3/6미래 성장2/6과거 실적0/6재무 건전성2/6배당0/6강점수익은 연간 196.17% 증가할 것으로 예상됩니다.동종업계 및 업계 대비 좋은 가치로 거래위험 분석의미 있는 시가총액이 없습니다($929K)마이너스 주주 지분지난 3개월 동안 주가 변동성이 US 시장과 비교했을 때 매우 높았습니다.지난 1년 동안 주주가 희석되었습니다.+ 위험 1건 추가모든 위험 점검 보기RKLY.Q Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW473,263 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA473,263 investors already sharing narrativesYour Fair ValueUS$Current PriceUS$0.00769.9k% 고평가 내재 할인율Est. Revenue$PastFuture-3b1b2016201920222025202620282031Revenue US$1.2bEarnings US$203.9mAdvancedSet Fair ValueView all narrativesRockley Photonics Holdings Limited 경쟁사Sun Pacific HoldingSymbol: OTCPK:SNPWMarket cap: US$32.7kP2 SolarSymbol: OTCPK:PTOSMarket cap: US$901.8kDatavault AISymbol: NasdaqCM:DVLTMarket cap: US$241.7mPerasoSymbol: NasdaqCM:PRSOMarket cap: US$10.5m가격 이력 및 성과Rockley Photonics Holdings 주가의 최고가, 최저가 및 변동 요약과거 주가현재 주가US$0.00752주 최고가US$5.1452주 최저가US$0.0002베타0.551개월 변동-74.07%3개월 변동-96.54%1년 변동-99.83%3년 변동-99.93%5년 변동n/aIPO 이후 변동-99.93%최근 뉴스 및 업데이트공고 • Dec 11Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Rockley Photonics Holdings LimitedBragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against Rockley Photonics Holdings Limited (Rockley or the Company) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired Rockley common stock between November 2, 2022 and October 20, 2023, both dates inclusive (the Class Period). Investors have until January 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. The Rockley class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Rockley’s joint venture agreement (JV Agreement) with Hengtong Rockley Technology Co. Ltd. was in jeopardy because Jiangsu Hengtong Optic-Electric Co. Ltd. (Hengtong), Rockley’s joint venture partner, had acquired a majority interest in a company, Huawei Marine Networks Co. Ltd. (Huawei Marine) (later renamed HMN Tech), on the banned entities list maintained by the U.S. Bureau of Industry and Security of the U.S. Department of Commerce since 2019; (ii) the JV Agreement was in further jeopardy because in February 2021 the World Bank had invalidated a bid by Huawei Marine to build an undersea optical cable based on security concerns raised by the United States and other countries that China could use the infrastructure to spy on communications; (iii) the materially undisclosed risk that the JV Agreement could fail as a result of Hengtong’s acquisition of a majority interest in HMN Tech jeopardized Rockley’s joint venture revenues, launch schedule, business prospects, and ultimately Rockley’s solvency; (iv) Rockley did not have the customer base or customer commitments that defendants had represented to investors; and (v) Rockley did not have sufficient customer orders to allow it to develop and commercialize products, maintain and expand client relationships, reach cash flow break-even, or stave off bankruptcy following the Merger.공고 • Dec 06Rockley Photonics Begins Sampling Bioptx™ Biosensing Band and PlatformRockley Photonics has announced the sampling of the complete Bioptx™ Biosensing Band and Platform to strategic customers and partners. Rockley Photonics Bioptx™ Biosensing Band. The Bioptx™ Biosensing Band incorporates Rockley’s breakthrough short-wave infrared (SWIR) biosensing technology based on their proprietary photonic integrated circuit (PIC) chipset. By incorporating the SWIR spectrophotometer into a wearable capable of several days of measurement, Rockley has demonstrated continuous collection of spectral data which provides unique insights into tissue composition and dynamics. The platform delivers real-time streaming of the SWIR-based biomarkers of body temperature and hydration, alongside the LED-based photoplethysmography (PPG) biomarkers of heart rate, heart rate variability, respiratory rate, and blood oxygen saturation. Combined with the recently released Rockley Developer API, the platform creates a seamless solution for real-time monitoring of vital physiologic parameters.공고 • Nov 11Robbins Geller Rudman & Dowd LLP Announces the Rockley Class Action Lawsuit Charges Sc Health Holdings Limited, Sc Health Group Limited, Sin Capital Group Pte. Ltd. and Certain of Sc Health, Sin Capital Group Pte. LtdThe law firm of Robbins Geller Rudman & Dowd LLP announced that purchasers of SC Health Corporation and Rockley Photonics Holdings Limited securities between March 19, 2021 and January 23, 2023, inclusive (the “Class Period”) and purchasers directly in the March 2021 private investment in public equity of Rockley shares (the “PIPE Offering”) conducted in connection with the merger of SC Health and Rockley (the “Merger”) have until January 8, 2024 to seek appointment as lead plaintiff of the Rockleyclass action lawsuit. Captioned Grossman v. Sin, et al., No. 23-cv-9501 (C.D. Cal.), the Rockley class action lawsuit charges SC Health Holdings Limited, SC Health Group Limited, SIN Capital Group Pte. Ltd. and certain of SC Health, SIN Capital Group Pte. Ltd., and Rockley’s top executive officers with violations of the Securities Exchange Act of 1934. The Rockleyclass action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Rockley’s joint venture agreement (“JV Agreement”) with Hengtong Rockley Technology Co. Ltd. was in jeopardy because Jiangsu Hengtong Optic-Electric Co. Ltd. (“Hengtong”), Rockley’s joint venture partner, had acquired a majority interest in a company, Huawei Marine Networks Co. Ltd. (“Huawei Marine”) (later renamed HMN Tech), on the banned entities list maintained by the U.S. Bureau of Industry and Security of the U.S. Department of Commerce since 2019; (ii) the JV Agreement was in further jeopardy because in February 2021 the World Bank had invalidated a bid by Huawei Marine to build an undersea optical cable based on security concerns raised by the United States and other countries that China could use the infrastructure to spy on communications; (iii) the materially undisclosed risk that the JV Agreement could fail as a result of Hengtong’s acquisition of a majority interest in HMN Tech jeopardized Rockley’s joint venture revenues, launch schedule, business prospects, and ultimately Rockley’s solvency; (iv) Rockley did not have the customer base or customer commitments that defendants had represented to investors; and (v) Rockley did not have sufficient customer orders to allow it to develop and commercialize products, maintain and expand client relationships, reach cash flow break-even, or stave off bankruptcy following the Merger.공고 • Sep 27Rockley Photonics Advances Non-Invasive Blood Glucose MonitoringRockley Photonics continues to make rapid progress towards noninvasive glucose sensing using its proprietary silicon photonics platform. The technology platform enables short-wave infrared (SWIR) spectroscopy to be translated to a miniaturized, wearable form factor capable of making noninvasive biomarker measurements in humans. Through a combination of benchtop sensor verification with both simulated human skin and during preliminary human studies, Rockley has engineered the SWIR platform to measure glucose. Recent measurements performed using Rockley’s PIC technology in a benchtop version with a complex simulated tissue model showed that the technology is capable of measuring glucose with an accuracy of 5mg/dL. The results of an initial IRB-approved study involving 40 Type I and Type II diabetic subjects over a 10-week period also demonstrated significant progress towards the development of a noninvasive wearable glucose monitor. The study was conducted with attention to avoid spurious correlations and allowed for critical technology performance characteristics to be determined.공고 • Aug 10Rockley Photonics Advances Development of Its Wearable, Laser-Based Blood Pressure Monitor with Successful Completion of Human StudiesRockley Photonics announced the initial results from two important IRB-approved human studies using a first-generation Alpha prototype of their non-invasive and laser-based cuffless blood pressure monitor. This innovative, wearable device is currently in advanced development. The first study successfully demonstrated intra-subject tracking of blood pressure compared to measurements using an intra-arterial pressure transducer, or an A-line, which is the gold-standard method to continuously monitor blood pressure during surgery and in the ICU. Thirty (30) subjects participated in the study, where blood pressure changes were induced using a repeated leg press exercise. Utilizing only the Rockley laser-based signal and a single-point blood pressure calibration, blood pressure changes from -10 mmHg to +25 mmHg were within target accuracy according to both FDA recognized consensus standards ISO 81060-2 and IEEE 1708. Future studies will focus on expanded blood pressure ranges. A second longitudinal study followed subjects with repeat visits up to 34 days post calibration. Here, Rockley device predictions were compared to dual-observer auscultation measurements (cuff-based with split stethoscope). Subjects included both healthy and hypertensive adult volunteers between ages 18 and 71 years. Despite real-world variability in device placement, the use of multiple devices per subject, and higher reference error, the longitudinal study results were comparable to the A-line study over the same BP range, and within sight of meeting the ISO 81060-2 and IEEE 1708 accuracy targets. Notably, the error did not increase over the time period from initial calibration. Potential use cases for the device focus on management of hypertension in various patient populations, where frequent insight may be leveraged in challenging-to-monitor scenarios, such as those that experience white coat hypertension or undergo regular treatments for kidney disease or heart failure. Rockley plans to engage with FDA via the Q-sub process in the coming months to obtain feedback on future clinical study design and data analysis.공고 • Aug 03Rockley Photonics Holdings Limited Launches Developer Platform for Biomarker Data Collection in Free-Living ConditionsRockley Photonics announced that it completed its first free-living study focused on capturing live spectral data using the initial release of their API Developer Platform, Connect Edge mobile application and secure cloud. Rockley delivers an all-in-one sensor with novel short-wave infrared (SWIR) biomarkers being collected in real-time, along with device and accelerometer data. Used in tandem with Rockley's suite of Bioptx Band devices, including Bioptx™? Cardio, the Rockley Connect mobile application allows for the continuous transfer of wearable sensor data to Rockley's secure cloud environment. The Developer Platform provides access to live data to those engaged in commercial activities and research with Rockley. The Rockley Connect Edge app and cloud services captured high-resolution SWIR spectral data, LED-based photoplethysmography (PPG) and acceleration, via data streams spanning more than 80% of subjects' daily life (including sleep). Simultaneously, spectral biomarkers were calculated in Rockley's secure cloud environment; Both raw and processed data were delivered to researchers via web apps and APIs within minutes of capture. Information captured from the Bioptx™? band using the Connect Edge mobile application included heart rate, heart rate variability, respiratory rate, blood oxygen saturation, body temperature, and hydration status. The band was continuously connected to the app while the subjects were free to carry out normal activities of daily living during data collection, moving through a variety of wireless connectivity conditions.더 많은 업데이트 보기Recent updates공고 • Dec 11Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Rockley Photonics Holdings LimitedBragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against Rockley Photonics Holdings Limited (Rockley or the Company) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired Rockley common stock between November 2, 2022 and October 20, 2023, both dates inclusive (the Class Period). Investors have until January 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. The Rockley class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Rockley’s joint venture agreement (JV Agreement) with Hengtong Rockley Technology Co. Ltd. was in jeopardy because Jiangsu Hengtong Optic-Electric Co. Ltd. (Hengtong), Rockley’s joint venture partner, had acquired a majority interest in a company, Huawei Marine Networks Co. Ltd. (Huawei Marine) (later renamed HMN Tech), on the banned entities list maintained by the U.S. Bureau of Industry and Security of the U.S. Department of Commerce since 2019; (ii) the JV Agreement was in further jeopardy because in February 2021 the World Bank had invalidated a bid by Huawei Marine to build an undersea optical cable based on security concerns raised by the United States and other countries that China could use the infrastructure to spy on communications; (iii) the materially undisclosed risk that the JV Agreement could fail as a result of Hengtong’s acquisition of a majority interest in HMN Tech jeopardized Rockley’s joint venture revenues, launch schedule, business prospects, and ultimately Rockley’s solvency; (iv) Rockley did not have the customer base or customer commitments that defendants had represented to investors; and (v) Rockley did not have sufficient customer orders to allow it to develop and commercialize products, maintain and expand client relationships, reach cash flow break-even, or stave off bankruptcy following the Merger.공고 • Dec 06Rockley Photonics Begins Sampling Bioptx™ Biosensing Band and PlatformRockley Photonics has announced the sampling of the complete Bioptx™ Biosensing Band and Platform to strategic customers and partners. Rockley Photonics Bioptx™ Biosensing Band. The Bioptx™ Biosensing Band incorporates Rockley’s breakthrough short-wave infrared (SWIR) biosensing technology based on their proprietary photonic integrated circuit (PIC) chipset. By incorporating the SWIR spectrophotometer into a wearable capable of several days of measurement, Rockley has demonstrated continuous collection of spectral data which provides unique insights into tissue composition and dynamics. The platform delivers real-time streaming of the SWIR-based biomarkers of body temperature and hydration, alongside the LED-based photoplethysmography (PPG) biomarkers of heart rate, heart rate variability, respiratory rate, and blood oxygen saturation. Combined with the recently released Rockley Developer API, the platform creates a seamless solution for real-time monitoring of vital physiologic parameters.공고 • Nov 11Robbins Geller Rudman & Dowd LLP Announces the Rockley Class Action Lawsuit Charges Sc Health Holdings Limited, Sc Health Group Limited, Sin Capital Group Pte. Ltd. and Certain of Sc Health, Sin Capital Group Pte. LtdThe law firm of Robbins Geller Rudman & Dowd LLP announced that purchasers of SC Health Corporation and Rockley Photonics Holdings Limited securities between March 19, 2021 and January 23, 2023, inclusive (the “Class Period”) and purchasers directly in the March 2021 private investment in public equity of Rockley shares (the “PIPE Offering”) conducted in connection with the merger of SC Health and Rockley (the “Merger”) have until January 8, 2024 to seek appointment as lead plaintiff of the Rockleyclass action lawsuit. Captioned Grossman v. Sin, et al., No. 23-cv-9501 (C.D. Cal.), the Rockley class action lawsuit charges SC Health Holdings Limited, SC Health Group Limited, SIN Capital Group Pte. Ltd. and certain of SC Health, SIN Capital Group Pte. Ltd., and Rockley’s top executive officers with violations of the Securities Exchange Act of 1934. The Rockleyclass action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Rockley’s joint venture agreement (“JV Agreement”) with Hengtong Rockley Technology Co. Ltd. was in jeopardy because Jiangsu Hengtong Optic-Electric Co. Ltd. (“Hengtong”), Rockley’s joint venture partner, had acquired a majority interest in a company, Huawei Marine Networks Co. Ltd. (“Huawei Marine”) (later renamed HMN Tech), on the banned entities list maintained by the U.S. Bureau of Industry and Security of the U.S. Department of Commerce since 2019; (ii) the JV Agreement was in further jeopardy because in February 2021 the World Bank had invalidated a bid by Huawei Marine to build an undersea optical cable based on security concerns raised by the United States and other countries that China could use the infrastructure to spy on communications; (iii) the materially undisclosed risk that the JV Agreement could fail as a result of Hengtong’s acquisition of a majority interest in HMN Tech jeopardized Rockley’s joint venture revenues, launch schedule, business prospects, and ultimately Rockley’s solvency; (iv) Rockley did not have the customer base or customer commitments that defendants had represented to investors; and (v) Rockley did not have sufficient customer orders to allow it to develop and commercialize products, maintain and expand client relationships, reach cash flow break-even, or stave off bankruptcy following the Merger.공고 • Sep 27Rockley Photonics Advances Non-Invasive Blood Glucose MonitoringRockley Photonics continues to make rapid progress towards noninvasive glucose sensing using its proprietary silicon photonics platform. The technology platform enables short-wave infrared (SWIR) spectroscopy to be translated to a miniaturized, wearable form factor capable of making noninvasive biomarker measurements in humans. Through a combination of benchtop sensor verification with both simulated human skin and during preliminary human studies, Rockley has engineered the SWIR platform to measure glucose. Recent measurements performed using Rockley’s PIC technology in a benchtop version with a complex simulated tissue model showed that the technology is capable of measuring glucose with an accuracy of 5mg/dL. The results of an initial IRB-approved study involving 40 Type I and Type II diabetic subjects over a 10-week period also demonstrated significant progress towards the development of a noninvasive wearable glucose monitor. The study was conducted with attention to avoid spurious correlations and allowed for critical technology performance characteristics to be determined.공고 • Aug 10Rockley Photonics Advances Development of Its Wearable, Laser-Based Blood Pressure Monitor with Successful Completion of Human StudiesRockley Photonics announced the initial results from two important IRB-approved human studies using a first-generation Alpha prototype of their non-invasive and laser-based cuffless blood pressure monitor. This innovative, wearable device is currently in advanced development. The first study successfully demonstrated intra-subject tracking of blood pressure compared to measurements using an intra-arterial pressure transducer, or an A-line, which is the gold-standard method to continuously monitor blood pressure during surgery and in the ICU. Thirty (30) subjects participated in the study, where blood pressure changes were induced using a repeated leg press exercise. Utilizing only the Rockley laser-based signal and a single-point blood pressure calibration, blood pressure changes from -10 mmHg to +25 mmHg were within target accuracy according to both FDA recognized consensus standards ISO 81060-2 and IEEE 1708. Future studies will focus on expanded blood pressure ranges. A second longitudinal study followed subjects with repeat visits up to 34 days post calibration. Here, Rockley device predictions were compared to dual-observer auscultation measurements (cuff-based with split stethoscope). Subjects included both healthy and hypertensive adult volunteers between ages 18 and 71 years. Despite real-world variability in device placement, the use of multiple devices per subject, and higher reference error, the longitudinal study results were comparable to the A-line study over the same BP range, and within sight of meeting the ISO 81060-2 and IEEE 1708 accuracy targets. Notably, the error did not increase over the time period from initial calibration. Potential use cases for the device focus on management of hypertension in various patient populations, where frequent insight may be leveraged in challenging-to-monitor scenarios, such as those that experience white coat hypertension or undergo regular treatments for kidney disease or heart failure. Rockley plans to engage with FDA via the Q-sub process in the coming months to obtain feedback on future clinical study design and data analysis.공고 • Aug 03Rockley Photonics Holdings Limited Launches Developer Platform for Biomarker Data Collection in Free-Living ConditionsRockley Photonics announced that it completed its first free-living study focused on capturing live spectral data using the initial release of their API Developer Platform, Connect Edge mobile application and secure cloud. Rockley delivers an all-in-one sensor with novel short-wave infrared (SWIR) biomarkers being collected in real-time, along with device and accelerometer data. Used in tandem with Rockley's suite of Bioptx Band devices, including Bioptx™? Cardio, the Rockley Connect mobile application allows for the continuous transfer of wearable sensor data to Rockley's secure cloud environment. The Developer Platform provides access to live data to those engaged in commercial activities and research with Rockley. The Rockley Connect Edge app and cloud services captured high-resolution SWIR spectral data, LED-based photoplethysmography (PPG) and acceleration, via data streams spanning more than 80% of subjects' daily life (including sleep). Simultaneously, spectral biomarkers were calculated in Rockley's secure cloud environment; Both raw and processed data were delivered to researchers via web apps and APIs within minutes of capture. Information captured from the Bioptx™? band using the Connect Edge mobile application included heart rate, heart rate variability, respiratory rate, blood oxygen saturation, body temperature, and hydration status. The band was continuously connected to the app while the subjects were free to carry out normal activities of daily living during data collection, moving through a variety of wireless connectivity conditions.공고 • Jan 27Rockley Photonics Holdings Limited(NYSE:RKLY) dropped from S&P TMI IndexRockley Photonics Holdings Limited(NYSE:RKLY) dropped from S&P TMI Index공고 • Jan 24Rockley Photonics Holdings Limited Filed for BankruptcyRockley Photonics Holdings Limited filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of New York on January 23, 2023. The debtor listed its assets in the range of $50 million to $100 million and liabilities in the range of $100 million to $500 million. The debtor is represented by Dania Slim of Pillsbury Winthrop Shaw Pittman LLP as its legal counsel.공고 • Dec 17Rockley Photonics Announces Receipt of Notice from NYSE of Non-Compliance with Continued Listing StandardsRockley Photonics Holdings Limited announced that it received a notice from the New York Stock Exchange (“NYSE”) on December 9, 2022, indicating that the Company is not in compliance with NYSE’s continued listing standards, which require an average market capitalization of not less than $50 million over a 30 trading-day period and stockholders’ equity of not less than $50 million. The notice has no immediate impact on the listing of Rockley’s common stock on the NYSE, subject to the Company’s compliance with the NYSE’s other continued listing requirements, except that its ticker symbol will continue to have an added designation of “.BC” to indicate the status of its ordinary shares as below compliance with the NYSE continued listing standards. The “.BC” indicator will be removed when it regains compliance. Rockley intends to respond to the NYSE within ten business days of receipt of the notice of its intent to submit a business plan to the NYSE within 45 days that shows how the Company plans to regain compliance with this continued listing standard within 18 months from the date of the notice. If Rockley is unable to regain compliance, the NYSE may initiate procedures to suspend and delist its common stock.공고 • Dec 14Rockley Photonics Holdings Limited Announces Appointment of Richard Edward Kuntz as Director, with Effect from August 8, 2022Rockley Photonics Holdings Limited announced appointment of Richard Edward Kuntz as Director, with effect from August 8, 2022.공고 • Dec 13+ 2 more updatesRockley Photonics Holdings Limited Announces Management ChangesRockley Photonics Holdings Limited announced changes to its senior management team. These changes are intended to position the Company for its next phase of growth. Effective immediately, Richard A. Meier has been appointed president and will join the board of directors. Andrew Rickman has resigned as chief executive officer and will take on the role of executive chairman of Rockley. The company also announced that Dr. Caroline Brown is stepping down from the board to pursue other business interests. Dr. Brown served as chair of the audit committee of the board and a member of the nominating and corporate governance committee. The board has appointed Dr. Nicolaus Henke to the audit committee to fill the vacancy resulting from Dr. Brown’s departure. Brian Blaser will serve as the chair of the audit committee.Seeking Alpha • Dec 12Rockley Photonics promotes Richard Meier to CEO, replacing Andrew RickmanRockley Photonics (NYSE:RKLY) on Monday said it had appointed Richard Meier as its CEO, replacing Andrew Rickman. Rickman will serve as executive chairman. Additionally, RKLY said it had appointed Chad Becker as interim CFO. The company said it would retain an executive search firm and start a formal search for a permanent CFO. "These changes are intended to position the Company for its next phase of growth," RKLY said in a statement. Rockley (RKLY) stock earlier closed -37.2% at $0.25.공고 • Nov 17Rockley Photonics Demonstrates Compact 4-Kelvin Silicon Photonics Modulator Enabling Interconnect Technologies for Ultra-Sensitive Image Detection and Sensing DevicesRockley Photonics Holdings Limited announced a 4-Kelvin performance demonstration with its monolithic silicon photonics electro-absorption modulator technology that is key to the development of next-generation cryogenic interconnect technology. This advancement is intended to enable ultra-sensitive image detection and sensing devices to view and capture images more clearly and at longer distances, as well as in low-light situations and enables these devices to have a significantly reduced size and weight. UC Santa Barbara’s project utilizes Rockley’s powerful technology and will potentially advance detection and sensing capabilities in devices for a range of applications that require ultra-sensitive sensors. Possible applications include infrared and hyperspectral imagers and cameras that are used for night and day surveillance, aerial search and rescue, environmental remote sensing and chemical detection, ultra-sensitive neutrino detectors in particle accelerators, as well as interconnects for quantum computers. The cryogenic modulation experiment showed that the strong modulation of Rockley’s silicon photonics electro-absorption modulator at room temperature is maintained when it is cooled down to 4 Kelvin (-269.15 Celsius, -452.47 Fahrenheit) with almost no performance degradation. At these low temperatures, signal noise in camera detector arrays is reduced dramatically, resulting in increased sensitivity, and enabling devices or cameras to view clearer images and the ability to see longer distances and in low light. The ability of Rockley’s platform to maintain good performance and capture data at this very low temperature means that Rockley’s photonic integrated circuit technology can be used to make these ultra-sensitive detection devices smaller in size and weight, have a lower cost, and operate with lower power consumption.Major Estimate Revision • Nov 17Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$8.99m to US$3.54m. EPS estimate increased from -US$1.77 to -US$1.45 per share. Semiconductor industry in the US expected to see average net income decline 4.9% next year. Consensus price target down from US$5.60 to US$1.50. Share price fell 14% to US$0.32 over the past week.Board Change • Nov 16High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. Independent Director Caroline Brown is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Price Target Changed • Nov 12Price target increased to US$8.00Up from US$5.60, the current price target is an average from 2 analysts. New target price is 2,253% above last closing price of US$0.34. Stock is down 95% over the past year. The company is forecast to post a net loss per share of US$1.45 next year compared to a net loss per share of US$1.66 last year.Reported Earnings • Nov 12Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2022 results: EPS: US$0.092 (up from US$0.46 loss in 3Q 2021). Net income: US$12.0m (up US$70.0m from 3Q 2021). Revenue missed analyst estimates by 63%. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 140% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Semiconductor industry in the US.Seeking Alpha • Nov 09Rockley Non-GAAP EPS of $0.14 beats by $0.40, revenue of $0.56M misses by $0.94MRockley press release (NYSE:RKLY): Q3 Non-GAAP EPS of $0.14 beats by $0.40. Revenue of $0.56M (-69.4% Y/Y) misses by $0.94M. Guidance Looking ahead, the Company is focused on three priorities for the remainder of 2022 – sampling Bioptx units to its customers for their trials; completing its in-house and independent human studies for blood pressure; and commencing its initial human studies utilizing its Bioptx Pro module for additional biomarkers, including glucose, alcohol, and lactate. Successful execution of these priorities will provide the foundational platform for the Company as it anticipates further scaling of these technologies in 2023. Rockley believes that its 2022 revenues will be in the range of $3.2-$3.6 million and plans to provide its outlook for 2023 in the first quarter of 2023. Shares +5%.공고 • Oct 27+ 2 more updatesRockley Photonics Holdings Limited to Report Q3, 2022 Results on Nov 09, 2022Rockley Photonics Holdings Limited announced that they will report Q3, 2022 results After-Market on Nov 09, 2022공고 • Oct 21+ 1 more updateRockley Photonics Holdings Limited Appoints Richard A. "Randy" Meier as Chief Financial OfficerRockley Photonics Holdings Limited announced the appointment of Richard A. “Randy” Meier as chief financial officer (CFO), effective immediately. Meier will shape Rockley’s financial and commercialization strategies, and lead its finance, supply chain, quality, regulatory and compliance functions. An accomplished finance and operations leader with a rich background in healthcare therapeutics and medical devices, Meier joins Rockley from Intersect ENT, a leading global ear, nose, and throat (ENT) medical technology company, where he served as EVP and CFO. Meier was instrumental in the 2022 sale of the company to Medtronic. Meier previously served as president-international, EVP and CFO of Owens & Minor Inc., a global healthcare solutions company, EVP and CFO of Teleflex Inc., a provider of specialty medical devices, and as president and chief operating officer of Advanced Medical Optics Inc., which was acquired by Abbott Laboratories. He is currently lead independent director at BioMarin Pharmaceuticals Inc., and a supervisory board member at Syntellix AG.공고 • Oct 20Rockley Photonics Holdings Limited Completes Human Study Demonstrating Promising Intra-Subject Tracking Against Standard Blood Pressure Cuff, Utilizing Its Non-Invasive, Cuffless, and Laser-Based DeviceRockley Photonics Holdings Limited announced that it completed an IRB-approved human study measuring blood pressure that utilized its non-invasive, cuffless biosensing device, currently under development. Based on its innovative laser-based technology, Rockley’s powerful technique for monitoring blood pressure does not rely on subject demographics, unlike many current cuffless blood pressure devices. Continuous, accurate and convenient monitoring of blood pressure is expected to advance the early diagnosis and treatment of hypertension, which is a risk factor for other serious health problems, such as heart disease and stroke. The current standard of blood pressure measurement may not provide the full picture of an individual’s health because it is measured only periodically, usually at a medical appointment. Even daily blood pressure readings performed at home don’t capture enough essential information because they do not provide frequent, trending information or nighttime changes in blood pressure, which provide better predictions of cardiovascular risk. Data collected in Rockley’s proof of concept blood pressure study provides promising results. The next phase is a 200-participant human study, beginning this fall. This study will utilize Rockley’s next generation wearable devices and will include isometric and aerobic exercise-based protocols. An in-line arterial study with an accurate pressure monitoring catheter reference on 30 subjects is also planned for this fall. In addition to medical settings, other potential applications for non-invasive blood pressure measurement are clinical trials, sports and athletic training and workers in physically and mentally-demanding professions like fire fighters and construction workers.Seeking Alpha • Oct 20Rockley Photonics hires Richard Meier as CFORockley Photonics (NYSE:RKLY) said Thursday it appointed Richard Meier as president and CFO, effective immediately. Meier most recently served as EVP and CFO at medical technology firm Intersect ENT. He also previously worked at Owens & Minor, Teleflex, and Advanced Medical Optics. Meier replaces interim CFO Chad Becker, who took on the role after Mahesh Karanth stepped down.공고 • Oct 04Rockley Photonics Holdings Limited announced that it has received $12.4 million in fundingOn October 3, 2022, Rockley Photonics Holdings Limited closed the transaction. The company received $10,000,000 from existing lenders. The transaction included participation from Andrew Rickman, chairman and chief executive officer of the company for gross proceeds of $500,000. The agreement also creates a structure for the company to raise an additional $15,000,000 in the form of notes which would be convertible into the company's ordinary shares.Seeking Alpha • Oct 03Rockley Photonics raises additional financingRockley Photonics Holdings (NYSE:RKLY) has obtained $10M of financing from the holders of its Convertible Senior Secured Notes due 2026. The agreement also creates a structure for the Co. to work with these holders to explore up to $15M in net additional financing in the form of notes which would be convertible into Rockley’s ordinary shares. In connection with the investment from current holders, Andrew Rickman, Chairman and CEO, provided an additional $0.5M, bringing the total amount of financing to $10.5M.공고 • Sep 23Rockley Photonics Holdings Limited Unveils Next-Generation, Higher-Density Laser Spectrophotometer Chip for Wearable Health MonitoringRockley Photonics Holdings Limited announced that it has developed what it believes to be the world’s first micro-transfer-printed (mTP) silicon-photonics-based laser for commercial applications. This groundbreaking achievement is expected to allow Rockley to further increase the density and reduce the size of its high-density spectrophotometer chips — which are already the world’s smallest for broadband infrared wavelength laser spectrometry (covering 1000 nanometers of spectrum) and are smaller in area than LED-based solutions currently used in wearables. This advancement could potentially have a significant impact across a wide range of applications, including the design of exceptionally small wearable devices for the detection and measurement of multiple biomarkers. New silicon-photonics-based biosensing chips using mTP technology are expected to be available in the first half of 2024. The new chip technology should have no impact on the upcoming launch of Rockley’s Bioptx™ biosensing band nor on any current-generation products that Rockley and its customers are developing. With this breakthrough in the mTP of silicon-photonics-based lasers, Rockley has dramatically increased the laser density of its photonics integrated circuits (PICs) for biosensing, creating what it believes to be the world’s highest-density broad-wavelength laser spectrophotometer chip, surpassing its own previous achievements. Moreover, the mTP process is expected to reduce manufacturing costs and enable thinner, smaller footprint and higher-density chip designs. These attributes are powerful benefits for use in consumer and medtech devices and could facilitate the integration of Rockley’s biosensing technology into future tiny wearables. Leveraging the mTP process, the new PIC technology will integrate a laser-generating “membrane” with a thickness of only 4 microns. The potential applications for this higher-density and smaller-footprint chip technology extend beyond biosensing and health monitoring into other areas, such as ultra-small wearables, clothing, or XR/VR/AR headsets and glasses. This mTP breakthrough is the direct result of Rockley’s multi-year partnership with the Tyndall National Institute at University College Cork in Ireland, X-Celeprint Limited, and the Irish Photonics Integration Centre (IPIC), with funding support from the Irish government’s Science Foundation Ireland (SFI) and Disruptive Technologies Innovation Fund (DTIF). The project started five years ago with a focus on developing a custom mTP process for Rockley’s silicon photonics platform and has involved a multidisciplinary team of world-class engineers and researchers. This technology, along with many other Rockley innovations, is backed by a robust multidisciplinary patent portfolio of over 200 issued patents and 295 pending patents in total.Major Estimate Revision • Aug 23Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$9.24m to US$8.99m. Losses expected to increase from US$1.52 per share to US$1.77. Semiconductor industry in the US expected to see average net income growth of 10% next year. Consensus price target down from US$6.20 to US$5.60. Share price fell 17% to US$1.48 over the past week.Reported Earnings • Aug 12Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.94 loss per share (down from US$0.90 loss in 2Q 2021). Net loss: US$121.8m (loss widened 299% from 2Q 2021). Revenue missed analyst estimates by 32%. Earnings per share (EPS) also missed analyst estimates by 224%. Over the next year, revenue is forecast to grow 1,590%, compared to a 11% growth forecast for the industry in the US.공고 • Aug 11Rockley Photonics Holdings Limited Establishes Scientific Advisory Board of Prominent Scientists and Medical ExpertsRockley Photonics Holdings Limited announced the formation of a scientific advisory board (SAB) gathering world-renowned experts across several key disciplines in biomedical science and technology, including spectroscopy, diabetes technology, hydration science, and cardiology. The SAB will be chaired by Vish Kulkarni, senior vice president of commercial at Rockley Photonics. The initial members of the Rockley SAB include the following experts in their field: Mark A. Arnold, Ph.D. is the Edwin B. Green Chair in Laser Chemistry, professor of chemistry and director of the Center for Biocatalysis and Bioprocessing (CBB) at the University of Iowa. He is a widely recognized expert in the non-invasive optical monitoring of biomarkers such as glucose and urea. In 2016, Dr. Arnold received the Senior Spectroscopist Designation from the Society for Applied Spectroscopy. He has been the Fellow of the Society for Applied Spectroscopy since 2010 and was a collegiate fellow at the College of Liberal Arts and Sciences, University of Iowa from 2001 to 2006. Zahi A. Fayad, Ph.D. is a professor of Radiology and Medicine (cardiology) at the Icahn School of Medicine at Mount Sinai and holds the Lucy G. Moses Professorship in Medical Imaging and Bioengineering at the Icahn School of Medicine in New York. He is the founding director of Mount Sinai’s Biomedical Engineering and Imaging Institute and vice chair for research in the Department of Radiology at the Icahn School of Medicine at Mount Sinai. Dr. Fayad’s interdisciplinary and discipline-bridging research — from engineering to biology and from pre-clinical to clinical investigations — has been dedicated to the detection and prevention of cardiovascular disease, with many seminal contributions in the field of multimodality biomedical imaging, nanomedicine, AI/ML in Imaging, and digital mobile health. Dr. Fayad is a paid consultant for Rockley Photonics. Stavros Kavouras, Ph.D. is an assistant dean of graduate education and professor of nutrition at Arizona State University. He directs the Hydration Science Lab, where he is studying the mechanisms by which water intake can impact health and performance. His current research focuses on the effect of water intake on glucose regulation and its implication on children’s hydration and obesity. Dr. Kavouras has authored more than 150 peer-review articles and 9,000 citations and has given lectures in 29 countries. David C. Klonoff, M.D. is an endocrinologist specializing in the development and use of diabetes technology. He is the medical director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center in San Mateo, California, and is a Clinical Professor of Medicine at University of California San Francisco. Dr. Klonoff received the American Diabetes Association’s Outstanding Physician Clinician Award in 2019. He received an FDA Director’s Special Citation Award from the U.S. Food and Drug Administration in 2010 for outstanding contributions related to diabetes technology. In 2012, Dr. Klonoff was elected to the College of Fellows at the American Institute of Medical and Biological Engineering (AIMBE), representing the top 2% of the world’s medical and biological engineers. He is founding editor of the Journal of Diabetes Science and Technology.공고 • Aug 09Rockley Photonics Names Richard Kuntz, M.D., M.Sc., to Its Board of Directors, Effective August 8, 2022Rockley Photonics named Richard Kuntz, M.D., M.Sc., to its board of directors. Dr. Kuntz will join the board as an independent director, effective August 8, 2022. Prior to his 17 years at Medtronic, Dr. Kuntz was the founder and chief scientific officer of the Harvard Clinical Research Institute, a university-based contract research organization which coordinates National Institutes of Health (NIH) and industry clinical trials with the U.S. Food and Drug Administration. Additionally, he directed numerous multicenter clinical trials and authored more than 250 original peer-reviewed publications. Additionally, Dr. Kuntz served as an associate professor of medicine at Harvard Medical School, chief of the division of clinical biometrics, and as an interventional cardiologist in the division of cardiovascular diseases at the Brigham and Women’s Hospital in Boston. He also has served as a member of the board of governors of the Patient Centered Outcomes Research Institute (PCORI), part of the Affordable Care Act, from 2010-2018. Dr. Kuntz also served as an advisor to multiple national and regional committees, including the National Academy of Medicine (NAM): Leadership Consortium for a Value & Science-Driven Health System, and co-chair of the NAM Evidence Mobilization Action Committee; the NIH: National Center for Advancing Translational Science, and the NIH: Cures Acceleration Network. He is presently serving as a working group member of NIH: Helping to End Addiction Long-term® (HEAL) program. Dr. Kuntz graduated from Miami University and received his medical degree from Case Western Reserve University School of Medicine. He completed his residency and chief residency in internal medicine at the University of Texas Southwestern Medical School, Parkland Hospital, Dallas, and then completed fellowships in cardiovascular diseases and interventional cardiology at the Beth Israel Hospital and Harvard Medical School, Boston. Dr. Kuntz received his Master of Science in biostatistics from the Harvard T.H. Chan School of Public Health. Dr. Kuntz’s appointment expands Rockley’s board to nine members.Seeking Alpha • Aug 09Rockley Photonics signs supply agreement for non-invasive biosensing wristbandRockley Photonics (NYSE:RKLY) signed a supply agreement outlining the customer's initial purchase commitment for 2023 and received the first commercial purchase order for its non-invasive biomarker sensing wristbands from a global healthcare technology provider. The Bioptx Baseline devices included in this order will employ Rockley’s biosensing technology, a complete end-to-end solution. The initial units are expected to ship in Q4 2022, which could put Rockley's ground-breaking biosensing technology on the wrists of end-users by 2022 end. To support the demand, the company has established the manufacturing partnerships to provide high-volume production, which is planned for 2023.Seeking Alpha • Jul 26Rockley Photonics enter partnership with leading contract research organizationRockley Photonics (NYSE:RKLY) enters a new partnership with a top ten, global contract research organization (or CRO) that provides full-service clinical development services to biopharmaceutical customers. The partners will integrate Rockley’s health monitoring solutions into clinical research studies, including its Bioptx biosensing wristband, cloud services, and other elements of its biomarker sensing platform for continuous, near real-time, non-invasive measurement of multiple biomarkers. CRO is expected to use Rockley-powered remote monitoring wearables as a tool for researchers to better understand various factors affecting the health and well-being of trial participants. Dr. Andrew Rickman, chairman and CEO said, “Partnering with CROs expands our reach in medtech and creates exciting opportunities for clinicians and researchers to conduct decentralized clinical trials and gain crucial insights into the health and well-being of patients throughout the trial, regardless of their location. With the extended range of biomarker detection and the ability to monitor those biomarkers on a routine basis, Rockley-powered wearables are poised to add a new dimension to clinical research and bring us one step closer to realizing our goal of improving health outcomes for everyone.”공고 • Jul 22Rockley Photonics Holdings Limited to Report Q2, 2022 Results on Aug 11, 2022Rockley Photonics Holdings Limited announced that they will report Q2, 2022 results After-Market on Aug 11, 2022공고 • Jun 17Rockley Photonics Holdings Limited Announces Biosensing Technology Enters Evaluation Phase by Leading Consumer Wearables CustomerRockley Photonics Holdings Limited announced that one of its tier-1 consumer wearables customers has begun an evaluation program using Rockley's photonics-based sensing technology, which was recently shipped to the customer. Under the evaluation program, Rockley's comprehensive non-invasive biomarker measurement solutions will be assessed for potential integration into the customer's future wearable products. The tier-1 customer adds to Rockley's growing list of global consumer electronics manufacturers to receive shipments of Rockley's VitalSpex(TM) Pro technology, which is expected to enable the non-invasive measurement of alcohol, glucose, and lactate from a wrist-worn device. The consumer wearables customer is one of twelve consumer electronics customers actively contracted with Rockley. By incorporating Rockley's advanced biosensing technology, Rockley-powered wearable devices could enable the routine, near real-time, non-invasive monitoring of a wide range of biomarkers, including core body temperature, blood pressure, heart rate, blood oxygen, body hydration, alcohol, lactate, and glucose, among others.공고 • Jun 16+ 1 more updateRockley Photonics Announces Senior Leadership ChangesRockley Photonics Holdings Limited announced that Ciaran Rooney, vice president of strategic relationships, was promoted to senior vice president of corporate development. During his tenure, Mr. Rooney played a key role in the financing of the business through multiple financing rounds including the recent private placement and the Company’s IPO last August, and has led Rockley’s strategic initiatives, including corporate development, strategic partnerships, and key commercial and corporate relationships.공고 • May 14Rockley Photonics Holdings Limited Provides Revenue Guidance for the Fiscal Year 2022Rockley Photonics Holdings Limited provided revenue guidance for the fiscal year 2022. For the year, the company expects revenue to be between $20 million to $30 million.Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.33 loss per share (up from US$1.92 loss in 1Q 2021). Net loss: US$41.8m (loss narrowed 36% from 1Q 2021). Revenue missed analyst estimates by 69%. Earnings per share (EPS) also missed analyst estimates by 18%. Over the next year, revenue is forecast to grow 1,007%, compared to a 20% growth forecast for the industry in the US.공고 • May 05Rockley Photonics Holdings Limited Announces Shipment of Vitalspex Pro Biosensing Technology for Alcohol, Lactate, and Glucose MeasurementRockley Photonics Holdings Limited announced it has shipped its VitalSpex Pro technology for the non-invasive measurement of alcohol, glucose, and lactate to an early-access, tier-1 consumer wearables customer. The shipment of this advanced biomarker-sensing technology marks an important milestone in the progress of next-generation digital healthcare. Rockley intends to begin production of the Baseline version of its VitalSpex biosensing platform, which will measure biomarkers for blood oxygen, blood pressure, body hydration, core body temperature, heart rate, heart rate variation, and respiratory rate, in the second half of 2022. The Company plans to begin production of the Pro version of its VitalSpex biosensing platform in 2023, which will measure an extended range of biomarkers, including alcohol, glucose, and lactate.Breakeven Date Change • Apr 27No longer forecast to breakevenThe 5 analysts covering Rockley Photonics Holdings no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$123.2m in 2024. New consensus forecast suggests the company will make a loss of US$9.80m in 2024.Board Change • Apr 27High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Nicolaus Henke was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.공고 • Apr 21Rockley Photonics Holdings Limited Announces Termination of Chief Operating Officer, Amit NagraRockley Photonics Holdings Limited announced that in connection with activities to monetize ultra-high-speed fiber optic communication solutions, Chief Operating Officer, Amit Nagra’s employment was terminated on April 15, 2022. Mr. Nagra will receive severance in accordance with the terms of his employment agreement.공고 • Apr 13Rockley Photonics Holdings Limited to Report Q1, 2022 Results on Apr 27, 2022Rockley Photonics Holdings Limited announced that they will report Q1, 2022 results After-Market on Apr 27, 2022Recent Insider Transactions Derivative • Mar 30Chief Operating Officer exercised options to buy US$614k worth of stock.On the 25th of March, Amit Nagra exercised options to buy 150k shares at a strike price of around US$0.54, costing a total of US$80k. This transaction amounted to 34% of their direct individual holding at the time of the trade. Since September 2021, Amit has owned 33.26k shares directly. Company insiders have collectively bought US$584k more than they sold, via options and on-market transactions, in the last 12 months.Recent Insider Transactions • Mar 21Independent Director recently bought US$197k worth of stockOn the 18th of March, Brian Blaser bought around 47k shares on-market at roughly US$4.19 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$362k more in shares than they have sold in the last 12 months.Breakeven Date Change • Mar 11No longer forecast to breakevenThe 5 analysts covering Rockley Photonics Holdings no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$123.2m in 2024. New consensus forecast suggests the company will make a loss of US$9.80m in 2024.공고 • Mar 10Rockley Photonics Holdings Limited Revises Revenue Guidance for the Fiscal Year 2022Rockley Photonics Holdings Limited revised revenue guidance for the fiscal year 2022. For the year, the company expects revenue to be in the range of $20 million to $30 million.Breakeven Date Change • Mar 10Forecast to breakeven in 2024The 4 analysts covering Rockley Photonics Holdings expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 23% per year to 2023. The company is expected to make a profit of US$123.2m in 2024. Average annual earnings growth of 70% is required to achieve expected profit on schedule.공고 • Feb 17Rockley Photonics Appoints Nicolaus Henke as Independent Director and Member of Nominating & Corporate Governance CommitteeRockley Photonics announced that it named Nicolaus Henke to its board of directors. Dr. Henke will join the board as an independent director, effective February 16, 2022, and will serve on the Nominating & Corporate Governance Committee. Dr. Henke brings to the board over 35 years of business experience, including 30 years with McKinsey & Company. Currently, Dr. Henke serves on the board of directors of Innovations in Healthcare. He also serves on the dean’s advisory council for the Harvard Kennedy School. Dr. Henke’s appointment expands Rockley’s board to eight members.공고 • Feb 16+ 1 more updateRockley Photonics Promotes Industry Leaders to Key Senior RolesRockley Photonics Holdings Limited announced several senior leadership promotions to further accelerate the development of its biomarker sensing platform and to drive its opportunity in healthcare. Rockley announced the following executive vice president promotions: Hooman Abediasl has been promoted to EVP of product engineering. Abediasl is a co-founder of Rockley’s sensing product technology and brings a strong technical leadership background in laser-based imaging and sensing to his role. Sanjiv Kapoor has been promoted to EVP of operations, process technology and manufacturing. Kapoor authored eight patents and 18 peer-reviewed publications. Roozbeh Parsa has been promoted to EVP of commercial. Parsa authored or co-authored over 25 U.S. patents. He has extensive technical and commercial experience in semiconductor and optical MEMS sensing. Rockley announced the following senior vice president promotions: Casimir Wierzynski has been promoted to SVP of cloud and AI. Benjamin VerSteeg has been promoted to SVP of sensing product development. VerSteeg was the co-founder and CEO of TruTouch Technologies, which developed the first commercial predicate to Rockley’s wearable sensor technology and was acquired by the company.공고 • Feb 09Rockley Photonics Announces Bioptx™ Biomarker Sensing Platform for Professional Healthcare, Including First-of-its-Kind Non-Invasive, Continuous Biosensing WristbandRockley Photonics Holdings Limited announced the Bioptx™ platform of biomarker sensing products and solutions for the medical and healthcare market. The Bioptx healthcare sensing platform is expected to provide medical institutions, such as hospitals, research clinics, pharmaceutical companies, medical device manufacturers, and other healthcare providers, with the ability to monitor the general wellness of individuals. The Bioptx sensing platform will integrate various sensing capabilities, including Rockley’s patented silicon-photonics-based laser technology. Rockley’s technology has the potential to significantly enhance the range of biomarkers that can be detected and measured by current sensors. The expanded range of biomarkers will include core body temperature, blood pressure, body hydration, alcohol, lactate, and glucose trends, among others. These new measurement capabilities have the potential to transform healthcare by providing real-time insights into a variety of health conditions and by enabling early detection of multiple disease states.Recent Insider Transactions Derivative • Feb 03Chief Operating Officer exercised options to buy US$1.6m worth of stock.On the 27th of January, Amit Nagra exercised options to buy 450k shares at a strike price of around US$0.54, costing a total of US$241k. This transaction amounted to 1,265% of their direct individual holding at the time of the trade. Since September 2021, Amit's direct individual holding has increased from 33.26k shares to 35.58k. Company insiders have collectively bought US$406k more than they sold, via options and on-market transactions, in the last 12 months.공고 • Jan 28Rockley Photonics Holdings Limited, Annual General Meeting, May 16, 2022Rockley Photonics Holdings Limited, Annual General Meeting, May 16, 2022.공고 • Jan 22Rockley Photonics Reaches Key Milestone in the Development of Cuffless, Non-Invasive Blood Pressure Measurement on the Wrist, Potentially Enabling A New Measurement Technique for Cardiovascular HealthRockley Photonics Holdings Limited announced that the company has successfully completed the first stage of its human studies examining the measurement of blood pressure using Rockley’s biomarker sensing platform. In this pilot study, Rockley researchers have demonstrated that a photonics-based sensor worn on the wrist can measure blood pressure non-invasively. Instead of applying a blood pressure cuff, which can be awkward or inconvenient and cause discomfort for some, Rockley’s wearable wrist-worn solution has the potential to provide hassle-free, clinical-grade data about key cardiovascular indicators. The Rockley blood pressure sensing device used in the study features a uniquelaser-based approach and advanced algorithms employing Rockley’s cloud and AI capabilities. The signals produced by the Rockley sensor were compared directly with signals produced at the same time and location by an off-the-shelf photoplethysmography (PPG) module, which employs green light-emitting diodes (LED) and is the technology employed by most wearables on the market now, often with the aid of a blood pressure cuff for calibration. The signals from the Rockley sensor were shown to provide stronger correlation with the control blood pressure readings from a cuff than standard green-LED PPG signals. In addition to demonstrating blood pressure measurement, the study showed that Rockley’s wrist-based sensing platform produces a strong correlation of heart rate (HR) and heart rate variability (HRV) measurement with results from commonly used electrocardiogram (ECG) equipment.Breakeven Date Change • Jan 02Forecast to breakeven in 2024The 4 analysts covering Rockley Photonics Holdings expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$123.2m in 2024. Average annual earnings growth of 63% is required to achieve expected profit on schedule.Board Change • Jan 01High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Independent Director Caroline Brown is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.공고 • Dec 09Rockley Photonics Holdings Limited Announces Results of Preliminary Human Studies Involving Measurement of Core Body TemperatureRockley Photonics Holdings Limited announced that the company has successfully completed the first stages of its preliminary human studies examining the measurement of core body temperature using its non-invasive biomarker sensing platform. In these studies, Rockley researchers have demonstrated that a photonics-based sensor detecting water spectra in different layers of the dermis can produce temperature measurements that correlate more closely with reference sensors for core body temperature than do auxiliary sensors like oral, ear, and infrared thermometers. By enabling the detection of core body temperature from a wearable device such as a smart watch or wristband, Rockley’s sensing platform has the potential to provide real-time insights about a variety of health conditions and enable the early detection of disease states. Core body temperature is a critical parameter that influences the body’s regular function and can affect one’s very survival. A person’s normal temperature can depend on a multitude of factors, and the human body constantly adapts its temperature to environmental conditions.Because today’s common measurement tools and thermometers are designed for convenience, they cannot readily measure the temperature inside the body and therefore may not always reflect the body’s true core temperature. Rockley’s wearable sensing platform probes beneath the surface of the skin to measure core body temperature in a non-invasive and continuous manner. The Rockley sensing platform uses photonic integrated circuit (PIC) sensors to generate numerous discrete, narrow-linewidth laser wavelengths across a wide spectral range. These laser wavelengths can detect a level of detail beyond today’s LED-based sensors and are therefore able to discern varying signatures of water absorption. Rockley’s platform can determine core body temperature by comparing these signatures to known properties of the water absorbance spectrum.Recent Insider Transactions • Nov 26Lead Independent Director recently bought US$165k worth of stockOn the 23rd of November, William Huyett bought around 25k shares on-market at roughly US$6.59 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.Reported Earnings • Nov 19Third quarter 2021 earnings released: US$0.54 loss per shareThird quarter 2021 results: Net loss: US$58.0m (flat on 3Q 2020).Seeking Alpha • Sep 13Rockley Photonics: Long Term Potential Of Wearables Chip Maker Is Truly VastRockley has developed a sensor capable of non-invasively tracking multiple biomarkers. The company recently became public via a merger with a SPAC. Revenue is guided to ramp heavily in the years ahead as Rockley eyes commercial launch in 2022.주주 수익률RKLY.QUS SemiconductorUS 시장7D-17.6%7.1%3.5%1Y-99.8%59.8%20.5%전체 주주 수익률 보기수익률 대 산업: RKLY.Q은 지난 1년 동안 59.8%의 수익을 기록한 US Semiconductor 산업보다 저조한 성과를 냈습니다.수익률 대 시장: RKLY.Q은 지난 1년 동안 20.5%를 기록한 US 시장보다 저조한 성과를 냈습니다.주가 변동성Is RKLY.Q's price volatile compared to industry and market?RKLY.Q volatilityRKLY.Q Average Weekly Movement46.9%Semiconductor Industry Average Movement13.6%Market Average Movement7.3%10% most volatile stocks in US Market16.1%10% least volatile stocks in US Market3.1%안정적인 주가: RKLY.Q의 주가는 지난 3개월 동안 US 시장보다 변동성이 컸습니다.시간에 따른 변동성: RKLY.Q의 주간 변동성은 지난 1년간 28%에서 47%로 증가했습니다.회사 소개설립직원 수CEO웹사이트2013302Randy Meierwww.rockleyphotonics.com더 보기Rockley Photonics Holdings Limited 기초 지표 요약Rockley Photonics Holdings의 순이익과 매출은 시가총액과 어떻게 비교됩니까?RKLY.Q 기초 통계시가총액US$929.23k순이익 (TTM)-US$166.29m매출 (TTM)US$5.43m0.2x주가매출비율(P/S)0.0x주가수익비율(P/E)RKLY.Q는 고평가되어 있습니까?공정 가치 및 평가 분석 보기순이익 및 매출최근 실적 보고서(TTM)의 주요 수익성 지표RKLY.Q 손익계산서 (TTM)매출US$5.43m매출원가US$7.43m총이익-US$2.00m기타 비용US$164.30m순이익-US$166.29m최근 보고된 실적Sep 30, 2022다음 실적 발표일해당 없음주당순이익(EPS)-1.25총이익률-36.75%순이익률-3,061.94%부채/자본 비율-222.7%RKLY.Q의 장기 실적은 어땠습니까?과거 실적 및 비교 보기View Valuation기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/03/16 06:22종가2023/03/14 00:00수익2022/09/30연간 수익2021/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Rockley Photonics Holdings Limited는 4명의 분석가가 다루고 있습니다. 이 중 1명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Tristan GerraBairdNathaniel Quinn BoltonNeedham & CompanyTimothy SavageauxNorthland Capital Markets1명의 분석가 더 보기
공고 • Dec 11Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Rockley Photonics Holdings LimitedBragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against Rockley Photonics Holdings Limited (Rockley or the Company) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired Rockley common stock between November 2, 2022 and October 20, 2023, both dates inclusive (the Class Period). Investors have until January 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. The Rockley class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Rockley’s joint venture agreement (JV Agreement) with Hengtong Rockley Technology Co. Ltd. was in jeopardy because Jiangsu Hengtong Optic-Electric Co. Ltd. (Hengtong), Rockley’s joint venture partner, had acquired a majority interest in a company, Huawei Marine Networks Co. Ltd. (Huawei Marine) (later renamed HMN Tech), on the banned entities list maintained by the U.S. Bureau of Industry and Security of the U.S. Department of Commerce since 2019; (ii) the JV Agreement was in further jeopardy because in February 2021 the World Bank had invalidated a bid by Huawei Marine to build an undersea optical cable based on security concerns raised by the United States and other countries that China could use the infrastructure to spy on communications; (iii) the materially undisclosed risk that the JV Agreement could fail as a result of Hengtong’s acquisition of a majority interest in HMN Tech jeopardized Rockley’s joint venture revenues, launch schedule, business prospects, and ultimately Rockley’s solvency; (iv) Rockley did not have the customer base or customer commitments that defendants had represented to investors; and (v) Rockley did not have sufficient customer orders to allow it to develop and commercialize products, maintain and expand client relationships, reach cash flow break-even, or stave off bankruptcy following the Merger.
공고 • Dec 06Rockley Photonics Begins Sampling Bioptx™ Biosensing Band and PlatformRockley Photonics has announced the sampling of the complete Bioptx™ Biosensing Band and Platform to strategic customers and partners. Rockley Photonics Bioptx™ Biosensing Band. The Bioptx™ Biosensing Band incorporates Rockley’s breakthrough short-wave infrared (SWIR) biosensing technology based on their proprietary photonic integrated circuit (PIC) chipset. By incorporating the SWIR spectrophotometer into a wearable capable of several days of measurement, Rockley has demonstrated continuous collection of spectral data which provides unique insights into tissue composition and dynamics. The platform delivers real-time streaming of the SWIR-based biomarkers of body temperature and hydration, alongside the LED-based photoplethysmography (PPG) biomarkers of heart rate, heart rate variability, respiratory rate, and blood oxygen saturation. Combined with the recently released Rockley Developer API, the platform creates a seamless solution for real-time monitoring of vital physiologic parameters.
공고 • Nov 11Robbins Geller Rudman & Dowd LLP Announces the Rockley Class Action Lawsuit Charges Sc Health Holdings Limited, Sc Health Group Limited, Sin Capital Group Pte. Ltd. and Certain of Sc Health, Sin Capital Group Pte. LtdThe law firm of Robbins Geller Rudman & Dowd LLP announced that purchasers of SC Health Corporation and Rockley Photonics Holdings Limited securities between March 19, 2021 and January 23, 2023, inclusive (the “Class Period”) and purchasers directly in the March 2021 private investment in public equity of Rockley shares (the “PIPE Offering”) conducted in connection with the merger of SC Health and Rockley (the “Merger”) have until January 8, 2024 to seek appointment as lead plaintiff of the Rockleyclass action lawsuit. Captioned Grossman v. Sin, et al., No. 23-cv-9501 (C.D. Cal.), the Rockley class action lawsuit charges SC Health Holdings Limited, SC Health Group Limited, SIN Capital Group Pte. Ltd. and certain of SC Health, SIN Capital Group Pte. Ltd., and Rockley’s top executive officers with violations of the Securities Exchange Act of 1934. The Rockleyclass action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Rockley’s joint venture agreement (“JV Agreement”) with Hengtong Rockley Technology Co. Ltd. was in jeopardy because Jiangsu Hengtong Optic-Electric Co. Ltd. (“Hengtong”), Rockley’s joint venture partner, had acquired a majority interest in a company, Huawei Marine Networks Co. Ltd. (“Huawei Marine”) (later renamed HMN Tech), on the banned entities list maintained by the U.S. Bureau of Industry and Security of the U.S. Department of Commerce since 2019; (ii) the JV Agreement was in further jeopardy because in February 2021 the World Bank had invalidated a bid by Huawei Marine to build an undersea optical cable based on security concerns raised by the United States and other countries that China could use the infrastructure to spy on communications; (iii) the materially undisclosed risk that the JV Agreement could fail as a result of Hengtong’s acquisition of a majority interest in HMN Tech jeopardized Rockley’s joint venture revenues, launch schedule, business prospects, and ultimately Rockley’s solvency; (iv) Rockley did not have the customer base or customer commitments that defendants had represented to investors; and (v) Rockley did not have sufficient customer orders to allow it to develop and commercialize products, maintain and expand client relationships, reach cash flow break-even, or stave off bankruptcy following the Merger.
공고 • Sep 27Rockley Photonics Advances Non-Invasive Blood Glucose MonitoringRockley Photonics continues to make rapid progress towards noninvasive glucose sensing using its proprietary silicon photonics platform. The technology platform enables short-wave infrared (SWIR) spectroscopy to be translated to a miniaturized, wearable form factor capable of making noninvasive biomarker measurements in humans. Through a combination of benchtop sensor verification with both simulated human skin and during preliminary human studies, Rockley has engineered the SWIR platform to measure glucose. Recent measurements performed using Rockley’s PIC technology in a benchtop version with a complex simulated tissue model showed that the technology is capable of measuring glucose with an accuracy of 5mg/dL. The results of an initial IRB-approved study involving 40 Type I and Type II diabetic subjects over a 10-week period also demonstrated significant progress towards the development of a noninvasive wearable glucose monitor. The study was conducted with attention to avoid spurious correlations and allowed for critical technology performance characteristics to be determined.
공고 • Aug 10Rockley Photonics Advances Development of Its Wearable, Laser-Based Blood Pressure Monitor with Successful Completion of Human StudiesRockley Photonics announced the initial results from two important IRB-approved human studies using a first-generation Alpha prototype of their non-invasive and laser-based cuffless blood pressure monitor. This innovative, wearable device is currently in advanced development. The first study successfully demonstrated intra-subject tracking of blood pressure compared to measurements using an intra-arterial pressure transducer, or an A-line, which is the gold-standard method to continuously monitor blood pressure during surgery and in the ICU. Thirty (30) subjects participated in the study, where blood pressure changes were induced using a repeated leg press exercise. Utilizing only the Rockley laser-based signal and a single-point blood pressure calibration, blood pressure changes from -10 mmHg to +25 mmHg were within target accuracy according to both FDA recognized consensus standards ISO 81060-2 and IEEE 1708. Future studies will focus on expanded blood pressure ranges. A second longitudinal study followed subjects with repeat visits up to 34 days post calibration. Here, Rockley device predictions were compared to dual-observer auscultation measurements (cuff-based with split stethoscope). Subjects included both healthy and hypertensive adult volunteers between ages 18 and 71 years. Despite real-world variability in device placement, the use of multiple devices per subject, and higher reference error, the longitudinal study results were comparable to the A-line study over the same BP range, and within sight of meeting the ISO 81060-2 and IEEE 1708 accuracy targets. Notably, the error did not increase over the time period from initial calibration. Potential use cases for the device focus on management of hypertension in various patient populations, where frequent insight may be leveraged in challenging-to-monitor scenarios, such as those that experience white coat hypertension or undergo regular treatments for kidney disease or heart failure. Rockley plans to engage with FDA via the Q-sub process in the coming months to obtain feedback on future clinical study design and data analysis.
공고 • Aug 03Rockley Photonics Holdings Limited Launches Developer Platform for Biomarker Data Collection in Free-Living ConditionsRockley Photonics announced that it completed its first free-living study focused on capturing live spectral data using the initial release of their API Developer Platform, Connect Edge mobile application and secure cloud. Rockley delivers an all-in-one sensor with novel short-wave infrared (SWIR) biomarkers being collected in real-time, along with device and accelerometer data. Used in tandem with Rockley's suite of Bioptx Band devices, including Bioptx™? Cardio, the Rockley Connect mobile application allows for the continuous transfer of wearable sensor data to Rockley's secure cloud environment. The Developer Platform provides access to live data to those engaged in commercial activities and research with Rockley. The Rockley Connect Edge app and cloud services captured high-resolution SWIR spectral data, LED-based photoplethysmography (PPG) and acceleration, via data streams spanning more than 80% of subjects' daily life (including sleep). Simultaneously, spectral biomarkers were calculated in Rockley's secure cloud environment; Both raw and processed data were delivered to researchers via web apps and APIs within minutes of capture. Information captured from the Bioptx™? band using the Connect Edge mobile application included heart rate, heart rate variability, respiratory rate, blood oxygen saturation, body temperature, and hydration status. The band was continuously connected to the app while the subjects were free to carry out normal activities of daily living during data collection, moving through a variety of wireless connectivity conditions.
공고 • Dec 11Bragar Eagel & Squire, P.C. Files Class Action Lawsuit Against Rockley Photonics Holdings LimitedBragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed against Rockley Photonics Holdings Limited (Rockley or the Company) in the United States District Court for the Central District of California on behalf of all persons and entities who purchased or otherwise acquired Rockley common stock between November 2, 2022 and October 20, 2023, both dates inclusive (the Class Period). Investors have until January 8, 2024 to apply to the Court to be appointed as lead plaintiff in the lawsuit. The Rockley class action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Rockley’s joint venture agreement (JV Agreement) with Hengtong Rockley Technology Co. Ltd. was in jeopardy because Jiangsu Hengtong Optic-Electric Co. Ltd. (Hengtong), Rockley’s joint venture partner, had acquired a majority interest in a company, Huawei Marine Networks Co. Ltd. (Huawei Marine) (later renamed HMN Tech), on the banned entities list maintained by the U.S. Bureau of Industry and Security of the U.S. Department of Commerce since 2019; (ii) the JV Agreement was in further jeopardy because in February 2021 the World Bank had invalidated a bid by Huawei Marine to build an undersea optical cable based on security concerns raised by the United States and other countries that China could use the infrastructure to spy on communications; (iii) the materially undisclosed risk that the JV Agreement could fail as a result of Hengtong’s acquisition of a majority interest in HMN Tech jeopardized Rockley’s joint venture revenues, launch schedule, business prospects, and ultimately Rockley’s solvency; (iv) Rockley did not have the customer base or customer commitments that defendants had represented to investors; and (v) Rockley did not have sufficient customer orders to allow it to develop and commercialize products, maintain and expand client relationships, reach cash flow break-even, or stave off bankruptcy following the Merger.
공고 • Dec 06Rockley Photonics Begins Sampling Bioptx™ Biosensing Band and PlatformRockley Photonics has announced the sampling of the complete Bioptx™ Biosensing Band and Platform to strategic customers and partners. Rockley Photonics Bioptx™ Biosensing Band. The Bioptx™ Biosensing Band incorporates Rockley’s breakthrough short-wave infrared (SWIR) biosensing technology based on their proprietary photonic integrated circuit (PIC) chipset. By incorporating the SWIR spectrophotometer into a wearable capable of several days of measurement, Rockley has demonstrated continuous collection of spectral data which provides unique insights into tissue composition and dynamics. The platform delivers real-time streaming of the SWIR-based biomarkers of body temperature and hydration, alongside the LED-based photoplethysmography (PPG) biomarkers of heart rate, heart rate variability, respiratory rate, and blood oxygen saturation. Combined with the recently released Rockley Developer API, the platform creates a seamless solution for real-time monitoring of vital physiologic parameters.
공고 • Nov 11Robbins Geller Rudman & Dowd LLP Announces the Rockley Class Action Lawsuit Charges Sc Health Holdings Limited, Sc Health Group Limited, Sin Capital Group Pte. Ltd. and Certain of Sc Health, Sin Capital Group Pte. LtdThe law firm of Robbins Geller Rudman & Dowd LLP announced that purchasers of SC Health Corporation and Rockley Photonics Holdings Limited securities between March 19, 2021 and January 23, 2023, inclusive (the “Class Period”) and purchasers directly in the March 2021 private investment in public equity of Rockley shares (the “PIPE Offering”) conducted in connection with the merger of SC Health and Rockley (the “Merger”) have until January 8, 2024 to seek appointment as lead plaintiff of the Rockleyclass action lawsuit. Captioned Grossman v. Sin, et al., No. 23-cv-9501 (C.D. Cal.), the Rockley class action lawsuit charges SC Health Holdings Limited, SC Health Group Limited, SIN Capital Group Pte. Ltd. and certain of SC Health, SIN Capital Group Pte. Ltd., and Rockley’s top executive officers with violations of the Securities Exchange Act of 1934. The Rockleyclass action lawsuit alleges that defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (i) Rockley’s joint venture agreement (“JV Agreement”) with Hengtong Rockley Technology Co. Ltd. was in jeopardy because Jiangsu Hengtong Optic-Electric Co. Ltd. (“Hengtong”), Rockley’s joint venture partner, had acquired a majority interest in a company, Huawei Marine Networks Co. Ltd. (“Huawei Marine”) (later renamed HMN Tech), on the banned entities list maintained by the U.S. Bureau of Industry and Security of the U.S. Department of Commerce since 2019; (ii) the JV Agreement was in further jeopardy because in February 2021 the World Bank had invalidated a bid by Huawei Marine to build an undersea optical cable based on security concerns raised by the United States and other countries that China could use the infrastructure to spy on communications; (iii) the materially undisclosed risk that the JV Agreement could fail as a result of Hengtong’s acquisition of a majority interest in HMN Tech jeopardized Rockley’s joint venture revenues, launch schedule, business prospects, and ultimately Rockley’s solvency; (iv) Rockley did not have the customer base or customer commitments that defendants had represented to investors; and (v) Rockley did not have sufficient customer orders to allow it to develop and commercialize products, maintain and expand client relationships, reach cash flow break-even, or stave off bankruptcy following the Merger.
공고 • Sep 27Rockley Photonics Advances Non-Invasive Blood Glucose MonitoringRockley Photonics continues to make rapid progress towards noninvasive glucose sensing using its proprietary silicon photonics platform. The technology platform enables short-wave infrared (SWIR) spectroscopy to be translated to a miniaturized, wearable form factor capable of making noninvasive biomarker measurements in humans. Through a combination of benchtop sensor verification with both simulated human skin and during preliminary human studies, Rockley has engineered the SWIR platform to measure glucose. Recent measurements performed using Rockley’s PIC technology in a benchtop version with a complex simulated tissue model showed that the technology is capable of measuring glucose with an accuracy of 5mg/dL. The results of an initial IRB-approved study involving 40 Type I and Type II diabetic subjects over a 10-week period also demonstrated significant progress towards the development of a noninvasive wearable glucose monitor. The study was conducted with attention to avoid spurious correlations and allowed for critical technology performance characteristics to be determined.
공고 • Aug 10Rockley Photonics Advances Development of Its Wearable, Laser-Based Blood Pressure Monitor with Successful Completion of Human StudiesRockley Photonics announced the initial results from two important IRB-approved human studies using a first-generation Alpha prototype of their non-invasive and laser-based cuffless blood pressure monitor. This innovative, wearable device is currently in advanced development. The first study successfully demonstrated intra-subject tracking of blood pressure compared to measurements using an intra-arterial pressure transducer, or an A-line, which is the gold-standard method to continuously monitor blood pressure during surgery and in the ICU. Thirty (30) subjects participated in the study, where blood pressure changes were induced using a repeated leg press exercise. Utilizing only the Rockley laser-based signal and a single-point blood pressure calibration, blood pressure changes from -10 mmHg to +25 mmHg were within target accuracy according to both FDA recognized consensus standards ISO 81060-2 and IEEE 1708. Future studies will focus on expanded blood pressure ranges. A second longitudinal study followed subjects with repeat visits up to 34 days post calibration. Here, Rockley device predictions were compared to dual-observer auscultation measurements (cuff-based with split stethoscope). Subjects included both healthy and hypertensive adult volunteers between ages 18 and 71 years. Despite real-world variability in device placement, the use of multiple devices per subject, and higher reference error, the longitudinal study results were comparable to the A-line study over the same BP range, and within sight of meeting the ISO 81060-2 and IEEE 1708 accuracy targets. Notably, the error did not increase over the time period from initial calibration. Potential use cases for the device focus on management of hypertension in various patient populations, where frequent insight may be leveraged in challenging-to-monitor scenarios, such as those that experience white coat hypertension or undergo regular treatments for kidney disease or heart failure. Rockley plans to engage with FDA via the Q-sub process in the coming months to obtain feedback on future clinical study design and data analysis.
공고 • Aug 03Rockley Photonics Holdings Limited Launches Developer Platform for Biomarker Data Collection in Free-Living ConditionsRockley Photonics announced that it completed its first free-living study focused on capturing live spectral data using the initial release of their API Developer Platform, Connect Edge mobile application and secure cloud. Rockley delivers an all-in-one sensor with novel short-wave infrared (SWIR) biomarkers being collected in real-time, along with device and accelerometer data. Used in tandem with Rockley's suite of Bioptx Band devices, including Bioptx™? Cardio, the Rockley Connect mobile application allows for the continuous transfer of wearable sensor data to Rockley's secure cloud environment. The Developer Platform provides access to live data to those engaged in commercial activities and research with Rockley. The Rockley Connect Edge app and cloud services captured high-resolution SWIR spectral data, LED-based photoplethysmography (PPG) and acceleration, via data streams spanning more than 80% of subjects' daily life (including sleep). Simultaneously, spectral biomarkers were calculated in Rockley's secure cloud environment; Both raw and processed data were delivered to researchers via web apps and APIs within minutes of capture. Information captured from the Bioptx™? band using the Connect Edge mobile application included heart rate, heart rate variability, respiratory rate, blood oxygen saturation, body temperature, and hydration status. The band was continuously connected to the app while the subjects were free to carry out normal activities of daily living during data collection, moving through a variety of wireless connectivity conditions.
공고 • Jan 27Rockley Photonics Holdings Limited(NYSE:RKLY) dropped from S&P TMI IndexRockley Photonics Holdings Limited(NYSE:RKLY) dropped from S&P TMI Index
공고 • Jan 24Rockley Photonics Holdings Limited Filed for BankruptcyRockley Photonics Holdings Limited filed a voluntary petition for reorganization under Chapter 11 in the US Bankruptcy Court for the Southern District of New York on January 23, 2023. The debtor listed its assets in the range of $50 million to $100 million and liabilities in the range of $100 million to $500 million. The debtor is represented by Dania Slim of Pillsbury Winthrop Shaw Pittman LLP as its legal counsel.
공고 • Dec 17Rockley Photonics Announces Receipt of Notice from NYSE of Non-Compliance with Continued Listing StandardsRockley Photonics Holdings Limited announced that it received a notice from the New York Stock Exchange (“NYSE”) on December 9, 2022, indicating that the Company is not in compliance with NYSE’s continued listing standards, which require an average market capitalization of not less than $50 million over a 30 trading-day period and stockholders’ equity of not less than $50 million. The notice has no immediate impact on the listing of Rockley’s common stock on the NYSE, subject to the Company’s compliance with the NYSE’s other continued listing requirements, except that its ticker symbol will continue to have an added designation of “.BC” to indicate the status of its ordinary shares as below compliance with the NYSE continued listing standards. The “.BC” indicator will be removed when it regains compliance. Rockley intends to respond to the NYSE within ten business days of receipt of the notice of its intent to submit a business plan to the NYSE within 45 days that shows how the Company plans to regain compliance with this continued listing standard within 18 months from the date of the notice. If Rockley is unable to regain compliance, the NYSE may initiate procedures to suspend and delist its common stock.
공고 • Dec 14Rockley Photonics Holdings Limited Announces Appointment of Richard Edward Kuntz as Director, with Effect from August 8, 2022Rockley Photonics Holdings Limited announced appointment of Richard Edward Kuntz as Director, with effect from August 8, 2022.
공고 • Dec 13+ 2 more updatesRockley Photonics Holdings Limited Announces Management ChangesRockley Photonics Holdings Limited announced changes to its senior management team. These changes are intended to position the Company for its next phase of growth. Effective immediately, Richard A. Meier has been appointed president and will join the board of directors. Andrew Rickman has resigned as chief executive officer and will take on the role of executive chairman of Rockley. The company also announced that Dr. Caroline Brown is stepping down from the board to pursue other business interests. Dr. Brown served as chair of the audit committee of the board and a member of the nominating and corporate governance committee. The board has appointed Dr. Nicolaus Henke to the audit committee to fill the vacancy resulting from Dr. Brown’s departure. Brian Blaser will serve as the chair of the audit committee.
Seeking Alpha • Dec 12Rockley Photonics promotes Richard Meier to CEO, replacing Andrew RickmanRockley Photonics (NYSE:RKLY) on Monday said it had appointed Richard Meier as its CEO, replacing Andrew Rickman. Rickman will serve as executive chairman. Additionally, RKLY said it had appointed Chad Becker as interim CFO. The company said it would retain an executive search firm and start a formal search for a permanent CFO. "These changes are intended to position the Company for its next phase of growth," RKLY said in a statement. Rockley (RKLY) stock earlier closed -37.2% at $0.25.
공고 • Nov 17Rockley Photonics Demonstrates Compact 4-Kelvin Silicon Photonics Modulator Enabling Interconnect Technologies for Ultra-Sensitive Image Detection and Sensing DevicesRockley Photonics Holdings Limited announced a 4-Kelvin performance demonstration with its monolithic silicon photonics electro-absorption modulator technology that is key to the development of next-generation cryogenic interconnect technology. This advancement is intended to enable ultra-sensitive image detection and sensing devices to view and capture images more clearly and at longer distances, as well as in low-light situations and enables these devices to have a significantly reduced size and weight. UC Santa Barbara’s project utilizes Rockley’s powerful technology and will potentially advance detection and sensing capabilities in devices for a range of applications that require ultra-sensitive sensors. Possible applications include infrared and hyperspectral imagers and cameras that are used for night and day surveillance, aerial search and rescue, environmental remote sensing and chemical detection, ultra-sensitive neutrino detectors in particle accelerators, as well as interconnects for quantum computers. The cryogenic modulation experiment showed that the strong modulation of Rockley’s silicon photonics electro-absorption modulator at room temperature is maintained when it is cooled down to 4 Kelvin (-269.15 Celsius, -452.47 Fahrenheit) with almost no performance degradation. At these low temperatures, signal noise in camera detector arrays is reduced dramatically, resulting in increased sensitivity, and enabling devices or cameras to view clearer images and the ability to see longer distances and in low light. The ability of Rockley’s platform to maintain good performance and capture data at this very low temperature means that Rockley’s photonic integrated circuit technology can be used to make these ultra-sensitive detection devices smaller in size and weight, have a lower cost, and operate with lower power consumption.
Major Estimate Revision • Nov 17Consensus forecasts updatedThe consensus outlook for 2022 has been updated. 2022 revenue forecast fell from US$8.99m to US$3.54m. EPS estimate increased from -US$1.77 to -US$1.45 per share. Semiconductor industry in the US expected to see average net income decline 4.9% next year. Consensus price target down from US$5.60 to US$1.50. Share price fell 14% to US$0.32 over the past week.
Board Change • Nov 16High number of new and inexperienced directorsThere are 10 new directors who have joined the board in the last 3 years. The company's board is composed of: 10 new directors. 2 experienced directors. No highly experienced directors. Independent Director Caroline Brown is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Price Target Changed • Nov 12Price target increased to US$8.00Up from US$5.60, the current price target is an average from 2 analysts. New target price is 2,253% above last closing price of US$0.34. Stock is down 95% over the past year. The company is forecast to post a net loss per share of US$1.45 next year compared to a net loss per share of US$1.66 last year.
Reported Earnings • Nov 12Third quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindThird quarter 2022 results: EPS: US$0.092 (up from US$0.46 loss in 3Q 2021). Net income: US$12.0m (up US$70.0m from 3Q 2021). Revenue missed analyst estimates by 63%. Earnings per share (EPS) exceeded analyst estimates. Revenue is forecast to grow 140% p.a. on average during the next 3 years, compared to a 7.1% growth forecast for the Semiconductor industry in the US.
Seeking Alpha • Nov 09Rockley Non-GAAP EPS of $0.14 beats by $0.40, revenue of $0.56M misses by $0.94MRockley press release (NYSE:RKLY): Q3 Non-GAAP EPS of $0.14 beats by $0.40. Revenue of $0.56M (-69.4% Y/Y) misses by $0.94M. Guidance Looking ahead, the Company is focused on three priorities for the remainder of 2022 – sampling Bioptx units to its customers for their trials; completing its in-house and independent human studies for blood pressure; and commencing its initial human studies utilizing its Bioptx Pro module for additional biomarkers, including glucose, alcohol, and lactate. Successful execution of these priorities will provide the foundational platform for the Company as it anticipates further scaling of these technologies in 2023. Rockley believes that its 2022 revenues will be in the range of $3.2-$3.6 million and plans to provide its outlook for 2023 in the first quarter of 2023. Shares +5%.
공고 • Oct 27+ 2 more updatesRockley Photonics Holdings Limited to Report Q3, 2022 Results on Nov 09, 2022Rockley Photonics Holdings Limited announced that they will report Q3, 2022 results After-Market on Nov 09, 2022
공고 • Oct 21+ 1 more updateRockley Photonics Holdings Limited Appoints Richard A. "Randy" Meier as Chief Financial OfficerRockley Photonics Holdings Limited announced the appointment of Richard A. “Randy” Meier as chief financial officer (CFO), effective immediately. Meier will shape Rockley’s financial and commercialization strategies, and lead its finance, supply chain, quality, regulatory and compliance functions. An accomplished finance and operations leader with a rich background in healthcare therapeutics and medical devices, Meier joins Rockley from Intersect ENT, a leading global ear, nose, and throat (ENT) medical technology company, where he served as EVP and CFO. Meier was instrumental in the 2022 sale of the company to Medtronic. Meier previously served as president-international, EVP and CFO of Owens & Minor Inc., a global healthcare solutions company, EVP and CFO of Teleflex Inc., a provider of specialty medical devices, and as president and chief operating officer of Advanced Medical Optics Inc., which was acquired by Abbott Laboratories. He is currently lead independent director at BioMarin Pharmaceuticals Inc., and a supervisory board member at Syntellix AG.
공고 • Oct 20Rockley Photonics Holdings Limited Completes Human Study Demonstrating Promising Intra-Subject Tracking Against Standard Blood Pressure Cuff, Utilizing Its Non-Invasive, Cuffless, and Laser-Based DeviceRockley Photonics Holdings Limited announced that it completed an IRB-approved human study measuring blood pressure that utilized its non-invasive, cuffless biosensing device, currently under development. Based on its innovative laser-based technology, Rockley’s powerful technique for monitoring blood pressure does not rely on subject demographics, unlike many current cuffless blood pressure devices. Continuous, accurate and convenient monitoring of blood pressure is expected to advance the early diagnosis and treatment of hypertension, which is a risk factor for other serious health problems, such as heart disease and stroke. The current standard of blood pressure measurement may not provide the full picture of an individual’s health because it is measured only periodically, usually at a medical appointment. Even daily blood pressure readings performed at home don’t capture enough essential information because they do not provide frequent, trending information or nighttime changes in blood pressure, which provide better predictions of cardiovascular risk. Data collected in Rockley’s proof of concept blood pressure study provides promising results. The next phase is a 200-participant human study, beginning this fall. This study will utilize Rockley’s next generation wearable devices and will include isometric and aerobic exercise-based protocols. An in-line arterial study with an accurate pressure monitoring catheter reference on 30 subjects is also planned for this fall. In addition to medical settings, other potential applications for non-invasive blood pressure measurement are clinical trials, sports and athletic training and workers in physically and mentally-demanding professions like fire fighters and construction workers.
Seeking Alpha • Oct 20Rockley Photonics hires Richard Meier as CFORockley Photonics (NYSE:RKLY) said Thursday it appointed Richard Meier as president and CFO, effective immediately. Meier most recently served as EVP and CFO at medical technology firm Intersect ENT. He also previously worked at Owens & Minor, Teleflex, and Advanced Medical Optics. Meier replaces interim CFO Chad Becker, who took on the role after Mahesh Karanth stepped down.
공고 • Oct 04Rockley Photonics Holdings Limited announced that it has received $12.4 million in fundingOn October 3, 2022, Rockley Photonics Holdings Limited closed the transaction. The company received $10,000,000 from existing lenders. The transaction included participation from Andrew Rickman, chairman and chief executive officer of the company for gross proceeds of $500,000. The agreement also creates a structure for the company to raise an additional $15,000,000 in the form of notes which would be convertible into the company's ordinary shares.
Seeking Alpha • Oct 03Rockley Photonics raises additional financingRockley Photonics Holdings (NYSE:RKLY) has obtained $10M of financing from the holders of its Convertible Senior Secured Notes due 2026. The agreement also creates a structure for the Co. to work with these holders to explore up to $15M in net additional financing in the form of notes which would be convertible into Rockley’s ordinary shares. In connection with the investment from current holders, Andrew Rickman, Chairman and CEO, provided an additional $0.5M, bringing the total amount of financing to $10.5M.
공고 • Sep 23Rockley Photonics Holdings Limited Unveils Next-Generation, Higher-Density Laser Spectrophotometer Chip for Wearable Health MonitoringRockley Photonics Holdings Limited announced that it has developed what it believes to be the world’s first micro-transfer-printed (mTP) silicon-photonics-based laser for commercial applications. This groundbreaking achievement is expected to allow Rockley to further increase the density and reduce the size of its high-density spectrophotometer chips — which are already the world’s smallest for broadband infrared wavelength laser spectrometry (covering 1000 nanometers of spectrum) and are smaller in area than LED-based solutions currently used in wearables. This advancement could potentially have a significant impact across a wide range of applications, including the design of exceptionally small wearable devices for the detection and measurement of multiple biomarkers. New silicon-photonics-based biosensing chips using mTP technology are expected to be available in the first half of 2024. The new chip technology should have no impact on the upcoming launch of Rockley’s Bioptx™ biosensing band nor on any current-generation products that Rockley and its customers are developing. With this breakthrough in the mTP of silicon-photonics-based lasers, Rockley has dramatically increased the laser density of its photonics integrated circuits (PICs) for biosensing, creating what it believes to be the world’s highest-density broad-wavelength laser spectrophotometer chip, surpassing its own previous achievements. Moreover, the mTP process is expected to reduce manufacturing costs and enable thinner, smaller footprint and higher-density chip designs. These attributes are powerful benefits for use in consumer and medtech devices and could facilitate the integration of Rockley’s biosensing technology into future tiny wearables. Leveraging the mTP process, the new PIC technology will integrate a laser-generating “membrane” with a thickness of only 4 microns. The potential applications for this higher-density and smaller-footprint chip technology extend beyond biosensing and health monitoring into other areas, such as ultra-small wearables, clothing, or XR/VR/AR headsets and glasses. This mTP breakthrough is the direct result of Rockley’s multi-year partnership with the Tyndall National Institute at University College Cork in Ireland, X-Celeprint Limited, and the Irish Photonics Integration Centre (IPIC), with funding support from the Irish government’s Science Foundation Ireland (SFI) and Disruptive Technologies Innovation Fund (DTIF). The project started five years ago with a focus on developing a custom mTP process for Rockley’s silicon photonics platform and has involved a multidisciplinary team of world-class engineers and researchers. This technology, along with many other Rockley innovations, is backed by a robust multidisciplinary patent portfolio of over 200 issued patents and 295 pending patents in total.
Major Estimate Revision • Aug 23Consensus EPS estimates fall by 16%The consensus outlook for earnings per share (EPS) in 2022 has deteriorated. 2022 revenue forecast decreased from US$9.24m to US$8.99m. Losses expected to increase from US$1.52 per share to US$1.77. Semiconductor industry in the US expected to see average net income growth of 10% next year. Consensus price target down from US$6.20 to US$5.60. Share price fell 17% to US$1.48 over the past week.
Reported Earnings • Aug 12Second quarter 2022 earnings: EPS and revenues miss analyst expectationsSecond quarter 2022 results: US$0.94 loss per share (down from US$0.90 loss in 2Q 2021). Net loss: US$121.8m (loss widened 299% from 2Q 2021). Revenue missed analyst estimates by 32%. Earnings per share (EPS) also missed analyst estimates by 224%. Over the next year, revenue is forecast to grow 1,590%, compared to a 11% growth forecast for the industry in the US.
공고 • Aug 11Rockley Photonics Holdings Limited Establishes Scientific Advisory Board of Prominent Scientists and Medical ExpertsRockley Photonics Holdings Limited announced the formation of a scientific advisory board (SAB) gathering world-renowned experts across several key disciplines in biomedical science and technology, including spectroscopy, diabetes technology, hydration science, and cardiology. The SAB will be chaired by Vish Kulkarni, senior vice president of commercial at Rockley Photonics. The initial members of the Rockley SAB include the following experts in their field: Mark A. Arnold, Ph.D. is the Edwin B. Green Chair in Laser Chemistry, professor of chemistry and director of the Center for Biocatalysis and Bioprocessing (CBB) at the University of Iowa. He is a widely recognized expert in the non-invasive optical monitoring of biomarkers such as glucose and urea. In 2016, Dr. Arnold received the Senior Spectroscopist Designation from the Society for Applied Spectroscopy. He has been the Fellow of the Society for Applied Spectroscopy since 2010 and was a collegiate fellow at the College of Liberal Arts and Sciences, University of Iowa from 2001 to 2006. Zahi A. Fayad, Ph.D. is a professor of Radiology and Medicine (cardiology) at the Icahn School of Medicine at Mount Sinai and holds the Lucy G. Moses Professorship in Medical Imaging and Bioengineering at the Icahn School of Medicine in New York. He is the founding director of Mount Sinai’s Biomedical Engineering and Imaging Institute and vice chair for research in the Department of Radiology at the Icahn School of Medicine at Mount Sinai. Dr. Fayad’s interdisciplinary and discipline-bridging research — from engineering to biology and from pre-clinical to clinical investigations — has been dedicated to the detection and prevention of cardiovascular disease, with many seminal contributions in the field of multimodality biomedical imaging, nanomedicine, AI/ML in Imaging, and digital mobile health. Dr. Fayad is a paid consultant for Rockley Photonics. Stavros Kavouras, Ph.D. is an assistant dean of graduate education and professor of nutrition at Arizona State University. He directs the Hydration Science Lab, where he is studying the mechanisms by which water intake can impact health and performance. His current research focuses on the effect of water intake on glucose regulation and its implication on children’s hydration and obesity. Dr. Kavouras has authored more than 150 peer-review articles and 9,000 citations and has given lectures in 29 countries. David C. Klonoff, M.D. is an endocrinologist specializing in the development and use of diabetes technology. He is the medical director of the Dorothy L. and James E. Frank Diabetes Research Institute of Mills-Peninsula Medical Center in San Mateo, California, and is a Clinical Professor of Medicine at University of California San Francisco. Dr. Klonoff received the American Diabetes Association’s Outstanding Physician Clinician Award in 2019. He received an FDA Director’s Special Citation Award from the U.S. Food and Drug Administration in 2010 for outstanding contributions related to diabetes technology. In 2012, Dr. Klonoff was elected to the College of Fellows at the American Institute of Medical and Biological Engineering (AIMBE), representing the top 2% of the world’s medical and biological engineers. He is founding editor of the Journal of Diabetes Science and Technology.
공고 • Aug 09Rockley Photonics Names Richard Kuntz, M.D., M.Sc., to Its Board of Directors, Effective August 8, 2022Rockley Photonics named Richard Kuntz, M.D., M.Sc., to its board of directors. Dr. Kuntz will join the board as an independent director, effective August 8, 2022. Prior to his 17 years at Medtronic, Dr. Kuntz was the founder and chief scientific officer of the Harvard Clinical Research Institute, a university-based contract research organization which coordinates National Institutes of Health (NIH) and industry clinical trials with the U.S. Food and Drug Administration. Additionally, he directed numerous multicenter clinical trials and authored more than 250 original peer-reviewed publications. Additionally, Dr. Kuntz served as an associate professor of medicine at Harvard Medical School, chief of the division of clinical biometrics, and as an interventional cardiologist in the division of cardiovascular diseases at the Brigham and Women’s Hospital in Boston. He also has served as a member of the board of governors of the Patient Centered Outcomes Research Institute (PCORI), part of the Affordable Care Act, from 2010-2018. Dr. Kuntz also served as an advisor to multiple national and regional committees, including the National Academy of Medicine (NAM): Leadership Consortium for a Value & Science-Driven Health System, and co-chair of the NAM Evidence Mobilization Action Committee; the NIH: National Center for Advancing Translational Science, and the NIH: Cures Acceleration Network. He is presently serving as a working group member of NIH: Helping to End Addiction Long-term® (HEAL) program. Dr. Kuntz graduated from Miami University and received his medical degree from Case Western Reserve University School of Medicine. He completed his residency and chief residency in internal medicine at the University of Texas Southwestern Medical School, Parkland Hospital, Dallas, and then completed fellowships in cardiovascular diseases and interventional cardiology at the Beth Israel Hospital and Harvard Medical School, Boston. Dr. Kuntz received his Master of Science in biostatistics from the Harvard T.H. Chan School of Public Health. Dr. Kuntz’s appointment expands Rockley’s board to nine members.
Seeking Alpha • Aug 09Rockley Photonics signs supply agreement for non-invasive biosensing wristbandRockley Photonics (NYSE:RKLY) signed a supply agreement outlining the customer's initial purchase commitment for 2023 and received the first commercial purchase order for its non-invasive biomarker sensing wristbands from a global healthcare technology provider. The Bioptx Baseline devices included in this order will employ Rockley’s biosensing technology, a complete end-to-end solution. The initial units are expected to ship in Q4 2022, which could put Rockley's ground-breaking biosensing technology on the wrists of end-users by 2022 end. To support the demand, the company has established the manufacturing partnerships to provide high-volume production, which is planned for 2023.
Seeking Alpha • Jul 26Rockley Photonics enter partnership with leading contract research organizationRockley Photonics (NYSE:RKLY) enters a new partnership with a top ten, global contract research organization (or CRO) that provides full-service clinical development services to biopharmaceutical customers. The partners will integrate Rockley’s health monitoring solutions into clinical research studies, including its Bioptx biosensing wristband, cloud services, and other elements of its biomarker sensing platform for continuous, near real-time, non-invasive measurement of multiple biomarkers. CRO is expected to use Rockley-powered remote monitoring wearables as a tool for researchers to better understand various factors affecting the health and well-being of trial participants. Dr. Andrew Rickman, chairman and CEO said, “Partnering with CROs expands our reach in medtech and creates exciting opportunities for clinicians and researchers to conduct decentralized clinical trials and gain crucial insights into the health and well-being of patients throughout the trial, regardless of their location. With the extended range of biomarker detection and the ability to monitor those biomarkers on a routine basis, Rockley-powered wearables are poised to add a new dimension to clinical research and bring us one step closer to realizing our goal of improving health outcomes for everyone.”
공고 • Jul 22Rockley Photonics Holdings Limited to Report Q2, 2022 Results on Aug 11, 2022Rockley Photonics Holdings Limited announced that they will report Q2, 2022 results After-Market on Aug 11, 2022
공고 • Jun 17Rockley Photonics Holdings Limited Announces Biosensing Technology Enters Evaluation Phase by Leading Consumer Wearables CustomerRockley Photonics Holdings Limited announced that one of its tier-1 consumer wearables customers has begun an evaluation program using Rockley's photonics-based sensing technology, which was recently shipped to the customer. Under the evaluation program, Rockley's comprehensive non-invasive biomarker measurement solutions will be assessed for potential integration into the customer's future wearable products. The tier-1 customer adds to Rockley's growing list of global consumer electronics manufacturers to receive shipments of Rockley's VitalSpex(TM) Pro technology, which is expected to enable the non-invasive measurement of alcohol, glucose, and lactate from a wrist-worn device. The consumer wearables customer is one of twelve consumer electronics customers actively contracted with Rockley. By incorporating Rockley's advanced biosensing technology, Rockley-powered wearable devices could enable the routine, near real-time, non-invasive monitoring of a wide range of biomarkers, including core body temperature, blood pressure, heart rate, blood oxygen, body hydration, alcohol, lactate, and glucose, among others.
공고 • Jun 16+ 1 more updateRockley Photonics Announces Senior Leadership ChangesRockley Photonics Holdings Limited announced that Ciaran Rooney, vice president of strategic relationships, was promoted to senior vice president of corporate development. During his tenure, Mr. Rooney played a key role in the financing of the business through multiple financing rounds including the recent private placement and the Company’s IPO last August, and has led Rockley’s strategic initiatives, including corporate development, strategic partnerships, and key commercial and corporate relationships.
공고 • May 14Rockley Photonics Holdings Limited Provides Revenue Guidance for the Fiscal Year 2022Rockley Photonics Holdings Limited provided revenue guidance for the fiscal year 2022. For the year, the company expects revenue to be between $20 million to $30 million.
Reported Earnings • May 13First quarter 2022 earnings: EPS and revenues miss analyst expectationsFirst quarter 2022 results: US$0.33 loss per share (up from US$1.92 loss in 1Q 2021). Net loss: US$41.8m (loss narrowed 36% from 1Q 2021). Revenue missed analyst estimates by 69%. Earnings per share (EPS) also missed analyst estimates by 18%. Over the next year, revenue is forecast to grow 1,007%, compared to a 20% growth forecast for the industry in the US.
공고 • May 05Rockley Photonics Holdings Limited Announces Shipment of Vitalspex Pro Biosensing Technology for Alcohol, Lactate, and Glucose MeasurementRockley Photonics Holdings Limited announced it has shipped its VitalSpex Pro technology for the non-invasive measurement of alcohol, glucose, and lactate to an early-access, tier-1 consumer wearables customer. The shipment of this advanced biomarker-sensing technology marks an important milestone in the progress of next-generation digital healthcare. Rockley intends to begin production of the Baseline version of its VitalSpex biosensing platform, which will measure biomarkers for blood oxygen, blood pressure, body hydration, core body temperature, heart rate, heart rate variation, and respiratory rate, in the second half of 2022. The Company plans to begin production of the Pro version of its VitalSpex biosensing platform in 2023, which will measure an extended range of biomarkers, including alcohol, glucose, and lactate.
Breakeven Date Change • Apr 27No longer forecast to breakevenThe 5 analysts covering Rockley Photonics Holdings no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$123.2m in 2024. New consensus forecast suggests the company will make a loss of US$9.80m in 2024.
Board Change • Apr 27High number of new directorsThere are 6 new directors who have joined the board in the last 3 years. Independent Director Nicolaus Henke was the last director to join the board, commencing their role in 2022. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
공고 • Apr 21Rockley Photonics Holdings Limited Announces Termination of Chief Operating Officer, Amit NagraRockley Photonics Holdings Limited announced that in connection with activities to monetize ultra-high-speed fiber optic communication solutions, Chief Operating Officer, Amit Nagra’s employment was terminated on April 15, 2022. Mr. Nagra will receive severance in accordance with the terms of his employment agreement.
공고 • Apr 13Rockley Photonics Holdings Limited to Report Q1, 2022 Results on Apr 27, 2022Rockley Photonics Holdings Limited announced that they will report Q1, 2022 results After-Market on Apr 27, 2022
Recent Insider Transactions Derivative • Mar 30Chief Operating Officer exercised options to buy US$614k worth of stock.On the 25th of March, Amit Nagra exercised options to buy 150k shares at a strike price of around US$0.54, costing a total of US$80k. This transaction amounted to 34% of their direct individual holding at the time of the trade. Since September 2021, Amit has owned 33.26k shares directly. Company insiders have collectively bought US$584k more than they sold, via options and on-market transactions, in the last 12 months.
Recent Insider Transactions • Mar 21Independent Director recently bought US$197k worth of stockOn the 18th of March, Brian Blaser bought around 47k shares on-market at roughly US$4.19 per share. This was the largest purchase by an insider in the last 3 months. Insiders have collectively bought US$362k more in shares than they have sold in the last 12 months.
Breakeven Date Change • Mar 11No longer forecast to breakevenThe 5 analysts covering Rockley Photonics Holdings no longer expect the company to break even during the foreseeable future. The company was expected to make a profit of US$123.2m in 2024. New consensus forecast suggests the company will make a loss of US$9.80m in 2024.
공고 • Mar 10Rockley Photonics Holdings Limited Revises Revenue Guidance for the Fiscal Year 2022Rockley Photonics Holdings Limited revised revenue guidance for the fiscal year 2022. For the year, the company expects revenue to be in the range of $20 million to $30 million.
Breakeven Date Change • Mar 10Forecast to breakeven in 2024The 4 analysts covering Rockley Photonics Holdings expect the company to break even for the first time. New consensus forecast suggests losses will reduce by 23% per year to 2023. The company is expected to make a profit of US$123.2m in 2024. Average annual earnings growth of 70% is required to achieve expected profit on schedule.
공고 • Feb 17Rockley Photonics Appoints Nicolaus Henke as Independent Director and Member of Nominating & Corporate Governance CommitteeRockley Photonics announced that it named Nicolaus Henke to its board of directors. Dr. Henke will join the board as an independent director, effective February 16, 2022, and will serve on the Nominating & Corporate Governance Committee. Dr. Henke brings to the board over 35 years of business experience, including 30 years with McKinsey & Company. Currently, Dr. Henke serves on the board of directors of Innovations in Healthcare. He also serves on the dean’s advisory council for the Harvard Kennedy School. Dr. Henke’s appointment expands Rockley’s board to eight members.
공고 • Feb 16+ 1 more updateRockley Photonics Promotes Industry Leaders to Key Senior RolesRockley Photonics Holdings Limited announced several senior leadership promotions to further accelerate the development of its biomarker sensing platform and to drive its opportunity in healthcare. Rockley announced the following executive vice president promotions: Hooman Abediasl has been promoted to EVP of product engineering. Abediasl is a co-founder of Rockley’s sensing product technology and brings a strong technical leadership background in laser-based imaging and sensing to his role. Sanjiv Kapoor has been promoted to EVP of operations, process technology and manufacturing. Kapoor authored eight patents and 18 peer-reviewed publications. Roozbeh Parsa has been promoted to EVP of commercial. Parsa authored or co-authored over 25 U.S. patents. He has extensive technical and commercial experience in semiconductor and optical MEMS sensing. Rockley announced the following senior vice president promotions: Casimir Wierzynski has been promoted to SVP of cloud and AI. Benjamin VerSteeg has been promoted to SVP of sensing product development. VerSteeg was the co-founder and CEO of TruTouch Technologies, which developed the first commercial predicate to Rockley’s wearable sensor technology and was acquired by the company.
공고 • Feb 09Rockley Photonics Announces Bioptx™ Biomarker Sensing Platform for Professional Healthcare, Including First-of-its-Kind Non-Invasive, Continuous Biosensing WristbandRockley Photonics Holdings Limited announced the Bioptx™ platform of biomarker sensing products and solutions for the medical and healthcare market. The Bioptx healthcare sensing platform is expected to provide medical institutions, such as hospitals, research clinics, pharmaceutical companies, medical device manufacturers, and other healthcare providers, with the ability to monitor the general wellness of individuals. The Bioptx sensing platform will integrate various sensing capabilities, including Rockley’s patented silicon-photonics-based laser technology. Rockley’s technology has the potential to significantly enhance the range of biomarkers that can be detected and measured by current sensors. The expanded range of biomarkers will include core body temperature, blood pressure, body hydration, alcohol, lactate, and glucose trends, among others. These new measurement capabilities have the potential to transform healthcare by providing real-time insights into a variety of health conditions and by enabling early detection of multiple disease states.
Recent Insider Transactions Derivative • Feb 03Chief Operating Officer exercised options to buy US$1.6m worth of stock.On the 27th of January, Amit Nagra exercised options to buy 450k shares at a strike price of around US$0.54, costing a total of US$241k. This transaction amounted to 1,265% of their direct individual holding at the time of the trade. Since September 2021, Amit's direct individual holding has increased from 33.26k shares to 35.58k. Company insiders have collectively bought US$406k more than they sold, via options and on-market transactions, in the last 12 months.
공고 • Jan 28Rockley Photonics Holdings Limited, Annual General Meeting, May 16, 2022Rockley Photonics Holdings Limited, Annual General Meeting, May 16, 2022.
공고 • Jan 22Rockley Photonics Reaches Key Milestone in the Development of Cuffless, Non-Invasive Blood Pressure Measurement on the Wrist, Potentially Enabling A New Measurement Technique for Cardiovascular HealthRockley Photonics Holdings Limited announced that the company has successfully completed the first stage of its human studies examining the measurement of blood pressure using Rockley’s biomarker sensing platform. In this pilot study, Rockley researchers have demonstrated that a photonics-based sensor worn on the wrist can measure blood pressure non-invasively. Instead of applying a blood pressure cuff, which can be awkward or inconvenient and cause discomfort for some, Rockley’s wearable wrist-worn solution has the potential to provide hassle-free, clinical-grade data about key cardiovascular indicators. The Rockley blood pressure sensing device used in the study features a uniquelaser-based approach and advanced algorithms employing Rockley’s cloud and AI capabilities. The signals produced by the Rockley sensor were compared directly with signals produced at the same time and location by an off-the-shelf photoplethysmography (PPG) module, which employs green light-emitting diodes (LED) and is the technology employed by most wearables on the market now, often with the aid of a blood pressure cuff for calibration. The signals from the Rockley sensor were shown to provide stronger correlation with the control blood pressure readings from a cuff than standard green-LED PPG signals. In addition to demonstrating blood pressure measurement, the study showed that Rockley’s wrist-based sensing platform produces a strong correlation of heart rate (HR) and heart rate variability (HRV) measurement with results from commonly used electrocardiogram (ECG) equipment.
Breakeven Date Change • Jan 02Forecast to breakeven in 2024The 4 analysts covering Rockley Photonics Holdings expect the company to break even for the first time. New consensus forecast suggests the company will make a profit of US$123.2m in 2024. Average annual earnings growth of 63% is required to achieve expected profit on schedule.
Board Change • Jan 01High number of new and inexperienced directorsThere are 6 new directors who have joined the board in the last 3 years. The company's board is composed of: 6 new directors. 1 experienced director. No highly experienced directors. Independent Director Caroline Brown is the most experienced director on the board, commencing their role in 2019. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
공고 • Dec 09Rockley Photonics Holdings Limited Announces Results of Preliminary Human Studies Involving Measurement of Core Body TemperatureRockley Photonics Holdings Limited announced that the company has successfully completed the first stages of its preliminary human studies examining the measurement of core body temperature using its non-invasive biomarker sensing platform. In these studies, Rockley researchers have demonstrated that a photonics-based sensor detecting water spectra in different layers of the dermis can produce temperature measurements that correlate more closely with reference sensors for core body temperature than do auxiliary sensors like oral, ear, and infrared thermometers. By enabling the detection of core body temperature from a wearable device such as a smart watch or wristband, Rockley’s sensing platform has the potential to provide real-time insights about a variety of health conditions and enable the early detection of disease states. Core body temperature is a critical parameter that influences the body’s regular function and can affect one’s very survival. A person’s normal temperature can depend on a multitude of factors, and the human body constantly adapts its temperature to environmental conditions.Because today’s common measurement tools and thermometers are designed for convenience, they cannot readily measure the temperature inside the body and therefore may not always reflect the body’s true core temperature. Rockley’s wearable sensing platform probes beneath the surface of the skin to measure core body temperature in a non-invasive and continuous manner. The Rockley sensing platform uses photonic integrated circuit (PIC) sensors to generate numerous discrete, narrow-linewidth laser wavelengths across a wide spectral range. These laser wavelengths can detect a level of detail beyond today’s LED-based sensors and are therefore able to discern varying signatures of water absorption. Rockley’s platform can determine core body temperature by comparing these signatures to known properties of the water absorbance spectrum.
Recent Insider Transactions • Nov 26Lead Independent Director recently bought US$165k worth of stockOn the 23rd of November, William Huyett bought around 25k shares on-market at roughly US$6.59 per share. This was the largest purchase by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
Reported Earnings • Nov 19Third quarter 2021 earnings released: US$0.54 loss per shareThird quarter 2021 results: Net loss: US$58.0m (flat on 3Q 2020).
Seeking Alpha • Sep 13Rockley Photonics: Long Term Potential Of Wearables Chip Maker Is Truly VastRockley has developed a sensor capable of non-invasively tracking multiple biomarkers. The company recently became public via a merger with a SPAC. Revenue is guided to ramp heavily in the years ahead as Rockley eyes commercial launch in 2022.
